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Abstract
Urokinase (uPA) and urokinase receptor (uPAR) are present in the urinary
tract of people, mice, rats and cows. The presence of urokinase and urokinase
receptor in the urinary tract of dogs has not been documented. Documenting the
presence of uPA and uPAR in the urinary tract of healthy dogs will help
determine the role these proteins play in pathology of the urinary tract in further
research.
Urine was collected from fifty-four healthy dogs. A fluorescence assay was
developed using the fluorogenic substrate Z-Gly-Gly-Arg-AMC, HCl. This assay
documented presence of active uPA-like protein in concentrated urine. A direct
sandwich ELISA assay was developed using a mouse anti-mouse primary
antibody and a biotin labeled rabbit anti-human secondary antibody. This ELISA
documented presence of active and inactive uPA-like protein and measured
concentration of uPA-like protein in concentrated urine.
Tissues from the urinary tract of eleven normal dogs; four intact females,
five intact males and two castrated males; were collected from kidney, ureter,
urinary bladder, urethra, prostate and testicle. SDS-PAGE/Western blot analysis
using mouse anti-mouse, mouse anti-human and rabbit anti-human uPA
antibodies and a mouse anti-human uPAR antibody were used to identify uPAlike and uPAR-like protein on the basis of molecular weight and antigen-antibody
reactions.
Immunoprecipitation was employed to enhance identification uPA-like and
uPAR-like protein using mouse anti-mouse, mouse anti-human and rabbit antihuman uPA antibodies and a mouse anti-human uPAR antibody.
xiii

Immunohistochemistry was utilized to identify staining in specific cell types within
the urinary tract. The uPA antibodies used were directed against human and
mouse urokinase. The uPAR antibody used was directed against human
urokinase receptor.
A urokinase-like protein is present in urine from healthy dogs in small but
measurable quantities. Urokinase-like and urokinase receptor-like protein are
present in the urinary tract of the healthy dog. This distribution is similar to that
identified in people. The role of urokinase-like and urokinase receptor-like protein
in the urinary tract of the normal dog is yet to be defined.

xiv

Chapter 1 Introduction
1.1 Urinary Tract Surgery in Animals
Urinary tract surgery is performed in dogs to relieve urinary tract
obstruction due to neoplasia or urolithiasis, to correct congenital abnormalities or
to obtain biopsies. Surgical procedures include cystotomy, cystostomy, partial
cystectomy, nephrectomy, nephrotomy, ureteral implantation, urethrostomy and
urethrotomy. Post-operative hemorrhage is a potential complication of urinary
tract surgery, particularly following renal or lower urinary tract diversion surgery.
In some cases, post-operative hemorrhage may necessitate blood transfusion
and lead to extended hospitalization.1, 2
1.2 Factors Contributing to Post-Operative Urinary Tract Hemorrhage
Factors contributing to post-operative hemorrhage include: the vascularity
of penile tissue, continued mechanical disruption of blood clots due to urine flow
past the surgical site, and failure to achieve an adequate fibrin seal when the
urethrostomy is left to heal by second intention healing of urethrotomy closes
and the selected suture pattern for urethrostomy closures.2, 3
1.3 The Role of the Fibrinolytic System after Urinary Tract Surgery
The role of the fibrinolytic system in dogs after urinary tract surgery has
not been established. Some have alluded to the role of urokinase in excessive
post-operative hemorrhage after urethral surgery.2
1.4 Urokinase and Urokinase Receptor in the Urinary Tract
Urokinase or urokinase plasminogen activator (uPA) and urokinase
receptor or urokinase plasminogen activator receptor (uPAR) are present in the
tissues of the mammalian urinary tract. 4-6 The function of uPA and uPAR in the
1

urinary tract is not completely understood but they are important in development
of the tubular anatomy of the urinary tract and in maintaining patency within the
developing and mature urinary tract.7
The proteolytic activity of human urine and its ability to dissolve fibrin clots
has been known for decades and was discovered to be due to the presence of a
plasminogen activator, later named urokinase.5, 8, 9 Urokinase is known to be
increased in inflammatory and other pathological conditions of the urinary tract in
people.7, 10, 11 Quantification of uPA in canine urine and identification of urokinase
and urokinase receptor in tissues of the urinary tract may help in determining if
they have a role in fibrinolysis which may contribute to post operative
hemorrhage following urinary tract surgery in dogs. 11, 12
1.5 Clinical Significance in Dogs
Post-operative hemorrhage in dogs undergoing urinary tract surgery can
be substantial. Whether uPA has a substantial role in prolonged bleeding after
urinary tract surgery in dogs is unknown. If urokinase does play a significant role,
use of drugs such as ε-aminocaproic acid that competitively inhibit plasminogen
activator substances may be useful. ε-aminocaproic acid has been successfully
used in people to inhibit uPA and decrease bleeding during renal amyliodosis
and menstruation.13, 14 Anecdotal reports of ε-aminocaproic acid successfully
halting hemorrhage within the urinary tract are exist in veterinary medicine,
however, no controlled studies have been performed.15 Dosages of εaminocaproic acid have not been established for dogs.15
The function of uPA within the urinary tract of dogs is not known but might
be important in maintaining patency of the urinary tract in the face of hemorrhage
2

and in the embryologic development of the urinary tract, which is a complex
system of hollow tubes. Identifying and quantifying uPA and uPAR in the normal
canine urinary tract is an initial step in evaluating a possible role of uPA in the
fibrinolytic system of the normal canine urinary tract. A description of the
distribution of uPA and uPAR in urinary tract of normal dogs is the first step in the
identification of disease related changes in the distribution of uPA and uPAR.
1.6 Investigational Objectives
The objectives in this investigation were:
1. To identify and quantitate urokinase in the urine of healthy dogs.
2. To identify urokinase and urokinase receptor in the urinary tract of
healthy dogs.
3. To validate the use of antibodies directed against human uPA and
uPAR and mouse uPA for identification of uPA and uPAR in the urinary
tract of healthy dogs.
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Chapter 2 Literature Review
2.1 Introduction
The focus of this thesis is on the distribution of urokinase and urokinase
receptor in the urinary tract of the normal dog. These proteins play an important
role in the activation of the fibrinolytic system in the body, a system that is
integrally involved in hemostasis.
2.2 Hemostasis
Hemostasis refers to the prevention of blood loss through a vessel when
vascular integrity is lost. Hemostasis is achieved as the result of several integral
mechanisms. These mechanisms include vascular spasm, formation of a platelet
plug, formation of a blood clot as a result of blood coagulation, and formation of a
permanent seal through a fibrin plug.1 The final step in those vessels which are
able to restore patency is clot lysis.2

2.2.1 Vascular Constriction
Following trauma to a blood vessel, the autonomic nervous system,
myogenic spasm and humoral factors released from traumatized endothelium
combine together to reduce the flow of blood from the vessel. The majority of the
vasoconstriction is attributed to myogenic contraction. In very small vessels
platelet derived thromboxane A2 is responsible for most of the constriction.1, 2
Endothelin and bradykinin also contributes to vascular constriction.2

2.2.2 Platelet Plug Formation
Small holes within blood vessels are sealed with a platelet plug as
opposed to a blood clot. Platelets have many functional characteristics that allow
5

them to contribute to hemostasis. Actin, myosin and thrombosthenin allow
platelets to contract and expand. Remnants of endoplasmic reticulum and Golgi
apparatus mediate synthesis of enzymes and storage of calcium for contraction
and expansion. Platelets are capable of producing adenosine triphosphate (ATP)
and adenosine diphosphate (ADP) within mitochondria for energy for platelet
activity. Prostaglandins are synthesized within platelets. These prostaglandins
contribute to local vascular and tissue reactions like inflammation. Platelets
contain fibrin-stabilizing factor which is important in creating bonds and crosslinkages between fibrin molecules and fibers. Platelets also secrete growth factor
that causes vascular endothelial, smooth muscle and fibroblasts to multiply and
grow, allowing vascular repair. Platelet surfaces contain glycoproteins that
promote adhesion to injured endothelial cells and exposed vessel wall. Platelet
membranes also contains phospholipids that participate throughout the clotting
process 1
In the presence of vascular injury platelets undergo three reactions: 1.
Adhesion and shape change, 2. secretion, and 3. aggregation. Reactions occur
simultaneously. Following adhesion, contractile proteins cause release of
granules from the platelets that adhere to collagen in the vessel wall and von
Willebrand factor in the plasma. Platelets secrete adenosine phosphate (ADP)
and thromboxane A2 which activate and recruit more platelets to the forming
plug.1, 2 Prostaglandin I2 is secreted by surrounding intact vascular endothelium
inhibiting platelet aggregation past the site of injury by decreasing release of ADP
from extra platelets. The platelet cell membrane glycoprotein also inhibits
adherence to normal endothelium.2
6

2.2.3 Blood Coagulation and Fibrin Plug Formation
If the injury to a vessel is severe a blood clot will begin to form in 15 to 20
seconds. If the trauma has been minor, formation of this clot may take 1 to 2
minutes. The process is initiated by activated substances from the endothelium
and exposed collagen, platelets and blood proteins adhering to the vessel wall.
The clot can completely fill the end of a small vessel and within an hour begins to
retract.1
Fibrin plug formation occurs when the blood clot is invaded by fibroblasts,
creating connective tissue throughout the clot. This process begins within a few
hours of the blood clot formation and continues into organization of fibrous tissue
over 1 to 2 weeks.1

2.2.4 Clot Lysis
Clot lysis requires the activation of circulating plasminogen to plasmin. In
the initial stages of clot formation, plasminogen is trapped within the clot. Tissue
plasminogen activator is then released, which cleaves the plasminogen to
plasmin, allowing the clot to be removed.2, 3 In non-vascular tissues a similar
process is occurring. However, in non-vascular tissues urokinase is the
plasminogen activator which cleaves the plasminogen.3
2.3 The Coagulation System
The coagulation system is composed of more than a dozen factors which
interact in a complex cascade of reactions within blood vessels and in the
surrounding tissues to produce hemostasis (table 2.1 and figure 2.1). Most of the
numbered factors are circulating inactive serine proteases, except factors V and
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VIII and fibrinogen which are labile. The factors become activated after initiation
of coagulation. The coagulation pathway is divided into the intrinsic or contact
pathway, the extrinsic pathway and the common pathway.2, 4 Plasma in dogs
and people have similar activity of prothrombin. Dogs have higher concentrations
and activities of fibrinogen, factor VIII and contact factors (factor XII, prekallikrein,
high-molecular-weight-kininogen and factor IX).4, 5
Table 2.1. Coagulation Factors
Name
Factor I
Factor II
Factor III
Factor IV
Factor V
Factor VII
Factor VIII
Factor IX
Factor X
Factor XI
Factor XII
Factor XIII
Prekallikrein
High-molecular-weightkininogen
Platelets
Kallikrein
Protein C
Protein S

Synonym
Fibrinogen
Prothrombin
Tissue factor; tissue
thromboplastin
Calcium
Proaccelerin; labile factor
Proconvertin; stabile factor
Antihemophilac factor A
Christmas factor;
antihemophilic factor B
Stuart factor
Plasma thromboplastin
antecedent
Hageman factor
Fibrin-stabilizing factor
Fletcher factor
Fitzgerald factor, HMWK

Pathway
Common
Common
Extrinsic
All
Intrinsic/extrinsic
Intrinsic
Intrinsic/common
Intrinsic
Common
Intrinsic
Intrinsic
Common
Extrinsic
Intrinsic/extrinsic
Intrinsic/extrinsic
Intrinsic
Intrinsic/common
Common

2.3.1 The Extrinsic Pathway
The extrinsic pathway is activated when traumatized tissue in vascular
adventitia and surrounding tissues, i.e. muscle, release tissue factor (TF) from
the cell membranes. Tissue factor complexes with circulating blood coagulation
factor VII in the presence of calcium and phospholipids.2, 4 Factor VII is activated
by factors Xa and IXa or by factor XIIa. The factor VIIa-TF complex then
activates factor X which in turn activates factor IX.4 The activated factor X
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Figure 2.1. Coagulation Pathway: Blue arrows represent activation, Green broken arrows
represent inhibitors, Red dotted arrow represents upregulation.

complexes with tissue and platelet phospholipids, to form prothrombin activator.
Prothrombin activator splits prothrombin to thrombin. At this point factor V can
also split prothrombin to thrombin and thrombin itself can cause prothrombin to
split into active thrombin in the intrinsic cascade.2
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2.3.2 The Intrinsic Pathway
The intrinsic pathway is initiated by trauma to the blood vessel itself when
collagen in a damaged vessel wall is exposed. This trauma causes activation of
factor XII and release of platelet phospholipids.2 Factor XII complexes with factor
XI and high-molecular-weight-kininogen (HMWK), causing activation of factor XII.
Factor XIIa activates factor XI and prekallikrein. Kallikrein increases factor XII
activation. High-molecular-weight-kininogen binds to prekallikrein and factor XI
as a cofactor for the intrinsic pathway surface-mediated reactions.4 Factor IXa
combines with factor VIII in the presence of platelet phospholipids to activate
factor X.2
The complement system acts with the contact phase of blood coagulation.
The complement system is comprised of plasma proteins which give rise to
chemotaxis mediators, increased vascular permeability, opsonin activity,
phagocytic activity and cytolysis. Factor XIIa fragments initiate the classical
pathway of complement by activating C1.6

2.3.3 The Common Pathway
The result of both the intrinsic and extrinsic pathways is the conversion of
factor X to factor Xa. This is the starting point of the common pathway or the
phase of thrombus formation. Thrombin cleaves fibrinogen into fibrin monomers.
The initial clot is not cross-linked and is quite weak. Thrombin activates factor
XIII, present in plasma and platelets. Factor XIIIa then creates fibrin dimers by
cross-linking adjacent fibrin fibers. This gives the clot strength and durability.2, 4
Fibrinogen is an important protein in both the formation and lysis of blood
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clots. Fibrinogen is produced by hepatocytes and megakaryocytes and circulates
in the plasma. Fibrinogen is a symmetrical dimer which is cleaved by Factor IIa to
convert fibrinogen to fibrin. Once fibrin is formed it stacks with platelets and
thrombin to form a loose fibrin plug. The fibrin molecules are later cross-linked by
factor XIII to form a stable fibrin plug. This is where the fibrinolytic system begins
to dissolve the plug.
2.4 The Fibrinolytic System
Until the 1990’s the fibrinolytic system was regarded as being primarily
involved in the regulation of intravascular clot dissolution via activation of
plasminogen. This came from the knowledge that impairments in the fibrinolytic
system resulted in increased bleeding or thromboembolic disease. In more
recent research with knock-out mice it became evident that the fibrinolytic system
has a more global role in the body. Fibrinolysis is involved in many aspects of
cellular activity and tissue development, both beneficial and harmful to an
organism as well as thrombolysis.7 Some authors consider this system to be
more properly named the plasminogen system due to the role in many other
activities besides just resolution of fibrin clots within the vascular system.3
The fibrinolytic system has many components (table 2.2). The role of the
fibrinolytic system in mammals is the maintenance of patent vasculature during
thrombosis. It also functions during the inflammatory and maturation phases of
wound healing. Fibrinolysis occurs for in the testicle and the placenta.
Fibrinolysis is also important in angiogenesis, embryologic development, tissue
remodeling, and in the pathogenesis of neoplastic disease. 8-18
Tissue plasminogen activator (tPA) and urokinase (uPA) are the most
11

Table 2.2 Components of the Fibrinolytic System
Component
Molecular Mass, Mean
kDa
Plasma Conc
Plasminogen
92
0.2 mg/ml
Tissue-type
70
5-10 ng/ml
plasminogen activator
Urokinase
53, 33
1 ng/ml
Prekallikrein
Factor XII
α2-Antiplasmin
α2-Macroglobulin
Plasminogen activator
inhibitor type-1
Plasminogen activator
inhibitor type-2
C1-inhibitor

88
80
70
4 160
50

Histidine-rich
glycoprotein
Thrombin activated
inhibitor of fibrinolysis

75

Half-Life

Function

50 h
2-3 min

Proenzyme
Plasminogen
activator
Plasminogen
activator
Proenzyme
Proenzyme
Plasmin inhibitor
Protease inhibitor
Inhibitor of tPA and
uPA
Inhibitor of uPA and
two-chain tPA
Inhibitor of “contact
activation”
components
Plasminogen
binding
Attenuation of fibrin
cofactor activity

3-5 min

0.04 mg/ml
0.03 mg/ml
0.07 mg/ml

25 h
60 h
50 h

60 ng/ml

5-7 min

70
105

49

important mediators of plasminogen activation. The tPA mediated pathway is
primarily involved in the dissolution of blood clots within the vascular system. The
uPA-mediated pathway is activated to provide fibrinolysis for events including cell
migration, tissue remodeling and fibrosis formation. Outside of the vascular
system inhibitors of the fibrinolytic system balance the action of fibrinolysis and
include α2 antiplasmin, α2 macroglobulin, antithrombin III, α2 antitripsin, C2
inactivators, plasminogen activator inhibitor 1 (PAI 1) and plasminogen activator
inhibitor 2 (PAI 2).9, 19
Fibrinolytic activity in the blood is mediated by plasma and cellular
components. In people and dogs, the plasma fraction contributes approximately
30% of the fibrinolytic activity.20 Urokinase, tPA and PAI-1 and PAI-2 are not
detectable in plasma of healthy people.21 However, these enzymes are present in
normal circulating monocytes.21 Mononuclear phagocytes express uPA, uPAR
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and plasminogen activator inhibitor (PAI).22, 23 Neutrophils and platelets have
high density of uPAR in their membrane. The urokinase receptors bind uPA and
accelerate plasminogen activation and fibrinolysis.24-26 Cytokines such as
interferon gamma and tumor necrosis factor stimulate plasminogen activator (PA)
and PAI activity in monocytes.23
The plasma kinin-forming system consists of three plasma proteins that
interact with certain negatively charged surfaces or macromolecular complexes.
They participate in the contact phase of the intrinsic coagulation pathway to
induce fibrinolysis. 9, 27-30 The three plasma proteins are high molecular weight
kininogen (HK), coagulation factor XII (FXII), and prekallikrein.29 Factor XII
activation is induced by several mechanisms. Collagen contact and negatively
charged surface contact, HMWK (Fitzgerald factor) and Kallikrein (Fletcher
factor). Plasmin itself also activates Factor XII leading to fibrinolytic amplification.
9, 28

For optimal activation of Factor XII (Hageman factor) both HK and

prekallikrein must be present to participate in the contact phase of the intrinsic
coagulation pathway and help induce fibrinolysis. 9, 28 High molecular weight
kininogen binds to uPAR on the endothelial cell surface.29, 31 Some investigators
propose that high concentrations of these activators are in circulation for the
purpose of fibrinolysis.32 Others propose that the circulating concentrations are
low unless triggered by a thrombolytic event.9
2.5 Tissue Plasminogen Activator
Tissue plasminogen activator is one of the endogenous extrinsic plasminogen
activators. Tissue plasminogen activator has a high affinity for fibrin
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Figure 2.2 Fibrinolytic Cascade: Blue arrows represent activation, red arrows represent
inactivation

and is of primary importance for the lysis of clots in the circulatory system.7 It is a
serine protease with a molecular weight of approximately 70kDa. It is secreted as
a single chain glycoprotein. The proform has some intrinsic activity; however, the
two chain form (held by single disulfide bonds) that is produced after cleavage by
plasmin is the most active form. 28
Tissue plasminogen activator is produced by endothelial cells, human
keratinocytes, melanocytes and neurons. It is also produced in numerous human
neoplastic cell lines such as melanoma, neuroblastoma, ovarian, breast and
pancreatic cancer.8-11, 13, 14, 16 Tissue plasminogen activator is most active within
the vasculature and has a high affinity for fibrin or fibrin-bound plasminogen.
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Tissue plasminogen activator has increased activity in the presence of fibrin
which leads to localization of activity within a clot, enhanced fibrinolysis and
improved binding of plasminogen to fibrin clots.33 This all ensures continuous
plasminogen concentration during tPA-mediated thrombolysis. 9, 28
Tissue plasminogen activator bound to plasminogen activator inhibitor is
cleared from the circulation by hepatocytes endocytosis. This clearance is via
endocytosis. There are no cell surface receptors identified for tPA. 9, 28
2.6 Urokinase
The fibrinolytic activity of urokinase was discovered decades ago upon the
discovery that urine could dissolve blood clots.34 Urokinase is a chymotrypsin-like
serine protease and is the second of two endogenous extrinsic plasminogen
activators that are important in the conversion of circulating proenzyme
plasminogen into the active serine protease plasmin in the extravascular
tissues.7, 35 Urokinase promotes fibrinolysis by catalyzing the cleavage of
plasminogen to plasmin.36
Urokinase is a single-chain glycoprotein with a molecular weight of 53
kDa.28 The chemical structure of uPA is complex. It is composed of three
domains with 411 amino acids.37 The N-terminal domain (amino acids 9-45) or
light chain (scuPA) has a growth factor domain. This is called the amino terminal
fragment and is also known as CD87.38-40 This fragment is the region responsible
for urokinase receptor binding.41 The kringle domain (amino acids 46-143)
contains a sequence that interacts with PAI-1. Urokinase also binds to heparin by
this domain.37 The C-terminal catalytic domain (amino acids 144-411) is the Bchain or heavy chain. It has a carboxyl-terminal region with a serine protease
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domain.37 The two chains are linked by a peptide. Together they form active uPA
which is also called high molecular weight urokinase.28, 36 Both single and twochain forms of uPA bind to uPAR or low-density lipoprotein (LDL) receptors on
cell surface membranes.37 The C-terminal domain binds to plasminogen leading
to plasmin formation.
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Figure 2.3 Urokinase and its cleavage products

In the mouse and human uPA is produced by many cell types within the
body but is produced in the greatest quantity by renal epithelial cells of the
proximal and distal kidney tubules. 42-44 Urokinase is also synthesized in
glomerular visceral epithelial cells44, 45 and is known to be excreted in mammalian
urine.46-49 Urokinase is present in human urine in a 1:1 ratio with a uPA
inhibitor.47 The role of uPA within the urinary tract may be to ensure patency of in
the face of hemorrhage.49 Urokinase is also present in the human prostate and
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semen where it is believed to play a role in sperm motility and maturation, and in
the urothelium of the bovine urinary bladder.10, 11, 46, 50
2.7 Urokinase Receptor
Urokinase receptor is a membrane bound protein that binds uPA localizing
extracellular and basement membrane degradation that promotes cellular
migration and invasion (figure 2.4).51 Urokinase receptor is a 55-60 kDa
glycoprotein.52-54 Urokinase receptor is anchored to the plasma membrane of
cells by a glycosylphosphatidylinositol (GPI) lipid moiety or a GPI tail.40, 51, 55, 56
Urokinase receptor consists of three different domains: the uPA binding domain 1
(D1), the connecting domain 2 (D2) and the cell anchoring domain 3 (D3).55 The
presence of urokinase receptors (uPAR) located on cell surface membranes is
important, but not essential, for the activity of uPA within the tissues.37
Urokinase receptor binds both the inactive and active forms of uPA. 40
Once bound, the inactive form of urokinase becomes activated. Bound active
urokinase enzyme retains its enzymatic activity. These uPAR are upregulated in
several neoplastic cell lines and in inflammatory processes on neutrophil
membranes.26 Although uPAR is present in normal cells, upregulation leads to
the detrimental effects which have linked urokinase to tumor invasion in breast
cancer57 and inflammation. Urokinase-uPAR complexes on any cell surface have
proteolytic, cell migratory, adhesive and chemotactic effects and uPA-uPAR
participates in extravascular fibrinolysis.55 Extracellular matrix disruption occurs
because uPAR has high affinity for the extra-cellular matrix protein vitronectin.37
Urokinase receptor plays a role in invasion and migration of certain immune cells
including natural killer (NK) cells.51 Increased concentrations of uPA and uPAR
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have been shown to be associated with a poor prognosis for some cancer lines.
8-11, 13, 14, 16

In several studies increased plasma concentrations of uPAR have

been reported in patients with chronic myeloproliferative and neoplastic
diseases.58

Figure 2.4 Schematic representation of the relationship between uPA and uPAR. G, growth
factor-like domain; K, kringle domain; C, catalytic domain; D1, uPA binding domain of uPAR; D2,
connecting domain; D3, cell anchoring domain; PAI-1, plasminogen activator inhibitor-1.

Urokinase receptor facilitates clearance of uPA by cells. The receptor
bound uPA complexes with PAI-1 and is immediately internalized. The uPA is
degraded in the lysosomes.37 The LDL receptor family consists of α2macroglobulin receptors and very low-density lipoprotein receptor related protein.
All are located within the cell membrane. These receptors aid internalization of
the uPA/UPAR/PAI-1 complex through clatherin-coated pits in cell membranes.
Internalized uPAR is recycled to the cell surface to rebind with another uPA
molecule.28, 37 Urokinase and urokinase degradation products bind directly to the
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LDL receptor-relative protein/α2-macroglobulin receptor and are internalized for
degradation.37
Urokinase and uPAR have been localized in almost all cell types including
renal tubular epithelial cells, urothelium, granulocytes and macrophages,
fibroblast-like and vascular endothelial-like cells in rat tendon, human pulmonary
alveolar cells, umbilical vein endothelial cells and foreskin cells.59-62
2.8 Plasminogen and Plasmin
Plasminogen is a single chain glycoprotein with a molecular weight of 92
kDa. The molecule has five kringle-like domains that contain lysine binding sites
and C terminal domains. The kringle domains bind to fibrin, cell surfaces and
plasma inhibitor α2 antiplasmin.7 The kringle domains mediate the interactions of
plasminogen and plasmin with substrate inhibitors and cell membranes.
Plasminogen is a circulating zymogen present in all vasculature and body
tissues. Plasminogen is synthesized in the hepatocytes of mammals and is
eliminated primarily by catabolic degradation in the plasma.7 63 Secondary
elimination is accomplished by conversion of the plasminogen to plasmin in
areas of coagulation and clot formation.9, 28 Plasminogen is also synthesized by
the seminiferous tubules of the testis in the rat.63
Plasminogen is cleaved at the Arg561-Val562 bond into the two chain form of
plasmin.64 The N-terminal heavy (A) chain has effector sites that are lysine
binding sites. The light (B) chain has an active site homologous with other serine
proteases (thrombin, Factor Xa) that cleaves lysine-arginine bonds. The light
chain site allows plasmin to attack any peptide containing an arginine-lysine
residue like the C-terminal residues on the surface of fibrin.28, 65 These
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interactions are important for the activity of plasminogen and the localization of
proteolytic activity of plasmin.7 Plasmin also has the ability to cleave
plasminogen into lysine plasminogen that has a 20 times increased affinity for
fibrin.65 This conversions leads to increased reactivity with plasminogen
activators accelerates conversion of plasminogen to plasmin.9, 28
Plasmin inactivates elements of the coagulation cascade. Plasminogen is
present within a fibrin clot bound to fibrin. It is cleaved to plasmin by tPA, uPA or
kallikrein. Plasmin degrades fibrin into D-dimers and fibrin degradation products
(FDP’s).25 Plasmin inactivates Factor VIII, V and XII, this aids in lysis of the clot
by destroying these coagulation factors.1 Plasmin also degrades prekallikrein,
high molecular weight kallikrein and converts C3 to C3a in the complement
cascade. 9, 28
When a clot is formed inside a vessel, the plasminogen is trapped inside
the clot. The plasminogen does not become plasmin and begin clot lysis until it is
activated. Tissue plasminogen activator is released from the vascular
endothelium a day or so after the clot has stopped the bleeding. This results in
lysis of the clot via plasmin mediated fibrin breakdown.
Plasmin formation through the action of plasminogen activators is crucial
for inflammation and wound healing.23, 66 Granulocytes and monocytes are both
sources of plasminogen activator activity among leukocytes.23, 66 As cells are
attached to a site of wound inflammation, neutrophils use uPA bound to uPAR to
concentrate plasmin activity in the targeted tissue. By mobilizing proteolytic
degradation of fibrin rich blood clots, uPA bound to uPAR and leukocyte integrin
αMβ2, a membrane bound leukocyte integrin, influences neutrophil adhesion and
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Figure 2.5 Plasminogen and Plasmin. Glu-Plasminogen is the form secreted by the liver. The
kringle domains mediate interactions of plasminogen and plasmin with substrates, inhibitors and
cell membranes and are crucial for the activation of plasminogen and localization of the activity of
plasmin. Release of the N-terminal domain or PAP forms Lys-plasminogen which can be
activated in the absence of fibrin at a rate higher than Glu-plasminogen. The N-terminal heavy Achain contains all the kringle domains. The C-terminal light B-chain contains the catalytic sites.
The specificity of plasmin comes from the domains of its heavy chain

migration.25 This allows degradation of the provisional extracellular matrix by
binding to vitronectin and permits migration of the neutrophils and macrophages
through the tissue planes. 23, 67, 68 Plasmin is important in all tissue remodeling in
the face of wound healing because of degradation of fibrin-vitronectin matrices
and the glycoprotein constituents of basement membranes.66
Lysine analogs such as ∋-aminocaproic acid bind to lysine binding on the
N-terminal heavy chain of plasmin and compete with lysine-like sites of fibrin for
plasminogen. By binding of plasmin on fibrin they reduce fibrinolysis.69, 70
2.9 Endogenous Inhibitors of Fibrinolysis
Endogenous inhibitors of fibrinolysis are important in keeping the
fibrinolytic system in check. Interestingly, most of the activators of fibrinolysis are
inactive in the absence of the inhibitors.
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2.9.1 Inhibitors of Plasminogen and Plasmin
The primary inhibitor of plasmin and plasminogen is α2-antiplasmin (α2AP), which is located circulating in plasma and platelets. α2-Antiplasmin is
secreted by the liver as a 70 kDa glycoprotein.7 Alpha2-AP is important in
regulation of lysis of the fibrin matrix of a thrombus, providing intermittent
activation at local sites of fibrin deposition without initiating a systemic proteolytic
state.7, 28 The α2-AP is bound to fibrin at the C-terminal region, which is the first
site on fibrin to be degraded by plasmin. It reacts quickly with plasmin, forming an
irreversible bond at the lysine binding sites. The α2-AP is then partially degraded
by plasmin. The α2-AP works quickly when plasmin is in circulation. However,
when plasmin or plasminogen are bound to a cell surface, the lysine binding sites
are occupied and α2-AP acts more slowly as the plasmin is protected against α2AP inactiavtion.28, 65 Fibrin clots are reduced in size layer by layer to provide
temporary ability at sites of vascular injury.7
Alpha2-macroglobulin (α2-MG) is a 725 kDa glycoprotein which is also a
plasmin inhibitor but is only important if α2-AP capacity is exceeded by excess
circulating plasmin. The α2-MG can only inhibit circulating plasmin and is
ineffective against cell bound plasmin.9, 28 Alpha2-macroglobulin works at a much
slower rate than α2-AP.
Thrombin-activated fibrinolysis inhibitor (TAFI) is a newly identified
inhibitor which is secreted by the liver as a single chain 58 kDa glycoprotein. Its
antifibrinolytic activity consists of removing the C-terminal binding sites for
plasminogen and tPA which are present on the degraded fibrin surface.65 The
TAFI is activated by thrombin or plasmin.7 This system appears to operate on a
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threshold system by acting as the means of removing the C-terminal argininelysine groups from the surface of the degraded fibrin. In doing so the α2-AP which
binds to this site is decreased and the rate of plasmin formation is decreased
since plasminogen binds to the arginine-lysine sites.65
Other direct plasminogen and plasmin inhibitors include antithrombin III,
α2-antitrypsin and C2-inactivators. These inhibitors have some activity in vitro but
limited activity in plasma.28

2.9.2 Inhibitors of Plasminogen Activators
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2
(PAI-2) are important inhibitors of tPA and uPA. Plasminogen activator inhibitor 1
and PAI-2 are present in low concentrations in plasma. The concentrations are
increased during neoplasia, sepsis and inflammation. The PAIs are secreted in
response to thrombin, endotoxin, tumor necrosis factor (TNF) and interleukin-1
(IL-1). Increased concentrations of PAI-1 have been used as a negative
prognostic marker in certain cancers in people. 9, 28
The PAI-1 is synthesized by endothelial cells, hepatocytes and is stored in
the α granules of platelets. When platelets are activated, they release PAI-1,
increasing the local concentration of PAI-1 at a clot and therefore increasing the
proteolytic stability of fibrin matrix.7 The PAI-1 rapidly inactivates tPA by forming
a reversible complex. The activity of PAI-1 is decreased by activated protein C
increasing fibrinolysis.9
Plasminogen activator inhibitor-1 also forms a reversible complex with
single chain uPA and tPA and inhibits receptor bound uPA and tPA from causing
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plasminogen activation. Plasminogen activator inhibitor-1 forms a 1:1 complex
with tPA and uPA. Plasminogen activator-1 is present in plasma and other
biological fluids in an active and latent form. The active form does not require any
conformational change to produce its effect. Active PAI-1 can be spontaneously
reverted to latent PAI-1. Latent PAI-1 can be activated by phosphatidylinositol
which is present in phospholipids vesicles from cell membranes. The active PAI1 interacts with vitronectin, stabilizing the active PAI-1 and decreasing binding of
vitronectin to cellular receptors such as those for uPA and tPA.7
Plasminogen activator inhibitor-2 is expressed by placenta, monocytes
and macrophages. Plasminogen activator inhibitor-2 inhibits uPA very rapidly but
inhibits tPA very slowly. 9, 28
2.10 Fibrinolysis and the Dog
Dogs have a very potent fibrinolytic system compared to people,
particularly during pulmonary thromboembolism.71, 72 In one study, a single
induced pulmonary embolus remained in the pulmonary vasculature of a dog for
5 days.71 In people with a similar lesion, resolution is usually incomplete even
after one year.71 The difference may be because canine platelets reveal
plasminogen activator, tPA and uPA, and plasminogen activator inhibitor-1
activity, where as human platelets exhibit primarily PAI-1 activity. Endothelial
cells in the dog also secrete uPA and likely play a role in the breakdown of clots
in the pulmonary vasculature. Concentrations of uPA in the membranes of canine
platelets have been shown to be approximately 50 times greater than in
membranes of human platelets. 71 This difference may play an important role in
the lack of problems in veterinary patients with deep vein thrombosis and
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pulmonary thromboembolism compared to similar diseases, injuries and degrees
of immobility in people.
2.11 Urokinase and Urokinase Receptor in the Kidney
High concentrations of urokinase are synthesized in the kidney.40 In
particular synthesis of uPA is evident in the medullary rays and epithelial cells of
the proximal and distal kidney tubules in the mouse and human. 42-44 Urokinase
is also synthesized and bound in human glomerular visceral epithelial cells in
culture.44, 45 Urokinase and urokinase receptor appear to be very important in the
pathophysiology of many renal diseases.
Glomerulosclerosis causes progressive glomerular injury in people due to
an accumulation of extracellular matrix in the glomerular mesangium. This is a
common problem in diabetic nephropathy in people and has been shown in rats
and mice as well.73, 74 Glomerular mesangial cells are a major source of
extracellular matrix production in chronic glomerular disease and cultured
mesangial cells produce uPA, tPA and PAI-1. 75, 76 Since abnormal extracellular
matrix accumulation is often preceded or combined with an increased expression
of extracellular matrix degrading enzymes77, PAI-1 has been implicated as a
mediator of extracellular matrix accumulation in renal disease.78 In cultured
human mesangial cells, low-density-lipoprotein (LDL) appears to upregulate PAI1 synthesis and activity, and uPA and tPA after long term incubation in biphasic
patterns. Upregulation of PAI-1, uPA and tPA may be mediated by delayed
protein kinase C activation associated with increased PAI activity. Protein kinase
C is activated by diacylglycerol (DAG), a product of phosphatidylinositol.
Phosphatidylinositol turnover is stimulated by oxidized LDL in culture. In vivo this
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may favor an accumulation of matrix within the kidney leading to
glomerulosclerosis.79
Renal ischemia and reperfusion injury is mediated by plasminogen
activators as well as the previously described free radicals, leukocytes, cytokines
proteinases.80, 81 Renal ischemia/reperfusion injury is often encountered in
surgery particularly during procedures involving the vasculature or
transplantation.80 In a rabbit model of renal ischemia/reperfusion the expression
of uPA and tPA was down-regulated and PAI-1 was up-regulated in cell lysates
of the ischemic kidney compared to the non-ischemic kidney. Fibrinolytic activity
was also lower in the ischemic kidney than the non-ischemic kidney. Repression
of fibrinolysis may contribute to the progression of renal damage in this model. 80
In immune mediated nephritis or nephrotoxic nephritis, fibrin deposition,
glomerular cell proliferation and macrophage infiltration are present.82 Recovery
from this disease requires plasmin mediated fibrin degradation. Plasmin is
activated by tPA and uPA that are produced in the kidney.45, 83, 84 In many
glomerulonephropathies, fibrinolysis appears to be inhibited by increased local
release of PAI-1.85 Urokinase receptor may also have a role in the long term
development of glomerulosclerosis in these disease processes. Glomerular
uPAR is increased in an accelerated model of nephrotoxic nephritis in the rat.
Urokinase may facilitate local fibrinolysis by binding uPA and leading to
degradation of the glomerular matrix.86
2.12 Urokinase and Urokinase Receptor in the Ureter
Little is known about uPA and uPAR in the ureter. In the ureter of healthy people
uPA and uPAR exhibit weak to moderate immunohistochemical staining
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in the cytoplasm of both urothelial and stromal cells.87
2.13 Urokinase and Urokinase Receptor in the Urinary Bladder
Urokinase and uPAR have been extensively evaluated in people with
malignancy of the urinary bladder.88-90 Urokinase has increases significantly in
malignant cell lines and is believed be a negative prognostic marker.89, 90
Concentration of uPAR does not correlate with severity of disease.8
The urinary bladder functions as an impermeable barrier. 46, 91 In
mammals, sodium and potassium are transported across the epithelium of the
urinary bladder from the urine to the interstitial space. Sodium transport occurs
through amiloride-sensitive Na+ channels in the apical membrane. Once Na+ is in
the cell, it is extruded across the basolateral membrane by Na+- K+ ATPase in
exchange for K+ which is actively transported back into the cell via K+ channels in
the basolateral cell membrane. On average there is one amiloride-sensitive Na+
channel in the rabbit urinary bladder for every 40 µm2 of apical membrane. These
channels are hydrolyzed by endogenous uPA released from the kidney. After
exposure to urokinase, the normal Na+ channel loses its amiloride and becomes
unstable in the membrane.92 The significance of this relationship is unknown.
In cows, the urinary bladder urothelium is the source of urinary
plasminogen activators, including uPA. In other mammalian species, the kidney
is the primary source of urinary plasminogen activators .46 The significance of
this finding is unknown.
2.14 Urokinase and Urokinase Receptor in the Prostate
Evaluation of uPA and uPAR in the prostate is focused on prostate cancer
in people and models of prostatic disease in mice and rats.93-95 The prostate
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gland is comprised of different lobes that are easily distinguished in rats.96 In a
study by Wilson, plasminogen activity varied significantly when the variables of
age, region of the prostate and castration were evaluated. Activity in all lobes
was low at 4 months and increased in the dorsal and anterior lobes at 31 months.
Plasminogen activity in the lateral lobe did not change with age. Following
castration, plasminogen activity increased by 3 to 5 fold in the ventral lobe in 4,
18 and 31 month old rats. Involution also increased in the ventral lobe of the 4
and 18 month old rats. These differences may reflect changes in cell function
such as secretion, inflammatory tissue pathology, altered hormone regulation of
these glands or unknown factors.97
Ventral prostates in older Fischer 344 rats demonstrated 25 times greater
plasminogen activator activity per unit of protein than juvenile rats. As rat aged
the activity of urokinase versus tissue-type plasminogen activator changed.
Urokinase is predominant in the 4 and 16 month old rats. Tissue-type
plasminogen activator is more predominant in the 30 month old rats.100 These
findings are based on amiloride activity which is selective as a urokinase
inhibitor.100, 101
In people, the prostate is more commonly divided into zones and the
development of pathology is different for these specific zones.97 In men, 80% of
prostate cancer is seen in the peripheral zone of the gland.17 Proteases are
important in mediating cellular atrophy and changes in tissue organization which
occur in normal development and in pathologic conditions. One group of these
proteases is the plasminogen activators. Proteases may be important in
remodeling the extracellular matrix in the prostate during development. In men,
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several studies have shown that uPA is the predominant plasminogen activator in
malignant and hyperplastic prostate tissue.17, 98, 99
2.15 Urokinase and Urokinase Receptor in the Testicle
Urokinase and urokinase receptor have been identified in spermatozoa of
mice, rats, rhesus monkeys and men. 43, 50, 102-105 Mouse spermatozoa have uPA
bound to the cell surface which is believed to be acquired from genital tract
secretions and synthesized by epithelial cells in the caudal epididymis and vas
deferens.43 Binding of uPA occurs due to synthesis and subsequent presence of
uPAR by the germ cells during spermatogenesis.103 Urokinase is present in
Sertoli cells of the rat and rhesus monkey and the Sertoli cells have been shown
to secrete uPA in cycles with tPA.50, 106 Urokinase production is decreased in
cultured Sertoli cells of the rat by the presence of follicle stimulating hormone.104
Urokinase is higher in the first fraction of ejaculate than in the second, suggesting
a mainly prostatic origin. In cases of azoospermia in men, concentrations of
measured uPA are much lower than in normal semen.105 The role of uPA and
uPAR in semen is still unknown but may be linked to cases of infertility.
2.16 Urokinase and Urokinase Receptor in the Urethra
Urokinase and urokinase receptor in the urethra have not been reported.
2.17 Urokinase and Urine
The ability of urine to lyse clots has been recognized for many years.107-109
Fibrinolytic ability is known to come from urokinase, which is excreted into the
urine from the kidney in most species. Urine samples from people have been
collected in large quantities and dialyzed using column chromatography to
evaluate the forms of urokinase in urine and to measure their activity.110 Both
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high and low molecular weight forms of urokinase are present in urine from
people.110, 111
2.18 Clinical Importance of the Fibrinolytic System
2.18.1 Coagulopathies and Hypercoagulation
Coagulation and fibrinolysis are believed to occur simultaneously during
the active state of hemostasis. Two pathologic conditions of this system are
coagulopathies and hypercoagulable states.28
A coagulopathy due to derangements in the fibrinolytic system leads to
excessive fibrinolysis within the tissues. Increased circulating tissue plasminogen
activator within the vasculature would increase intravascular fibrinolysis.
Decreased concentration of α2-antiplasmin in circulation can produce a
coagulopathy.112-114 α2-antiplasmin concentration will decrease in response to the
activation of plasminogen which occurs in many fibrinolytic states.112 A PAI-1
deficiency could be the cause of increased tPA and may also increase circulating
uPA since PAI-1 inhibits both tPA and uPA.113 Antihemostatic effects of fibrin
degradation products in conditions such as in disseminated intravascular
coagulation (DIC) also lead to coagulopathies.
Hypercoagulation is the result of activated coagulation factors with
decreased resistance to thrombosis. In cases of inflammation and infections in
the horse and cow, consumption of protein C and antithrombin decreases the
host anticoagulant response to coagulation. In other words, a lack of
plasminogen activators secondary to increased PAIs and consumption of
circulating anticoagulants is occurring within the body.9 Therefore, thrombosis
occurs when inappropriate increases in fibrinolytic inhibitors reduce fibrinolysis.
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Inflammation, and ischemia can cause thrombosis by decreasing plasminogen,
plasminogen activators and Protein C. Antithrombin III, which inactivates Factor
Xa and thrombin, is also decreased in these disease states.3 Hypercoagulation
precedes clinical DIC.
Secondary fibrinolysis is a physiologic response to systemic large vessel
and microvascular thrombosis that occurs during hypercoagulation and DIC.
Excessive fibrin forms independent of activation of the coagulation cascade.
Inflammatory cells and platelets carry their own internal stores of
plasminogen activators and inhibitors to sites of inflammation and infection.
Urokinase receptor is produced and present on the cell membranes of
granulocytes and monocytes. Urokinase will bind to uPAR on granulocytes and
monocytes and be introduced to inflammatory sites by migrating cells. The
urokinase-type plasminogen system consisting of uPA, uPAR and inhibitors plays
an important role in neutrophil, macrophage and platelet activation, adhesion,
migration and extravasation.115 Granulocytes have the highest expression of
uPAR among blood cells. Tissue plasminogen activator and PAI-1 and 2 are also
present in granulocytes and monocytes. PAI-1 and uPA are present in the
platelets of dogs.71 Upregulation of the inflammatory systems in a case such as
sepsis causes derangements in the coagulation/hemostatic system, including
consumption of coagulation factors, increased coagulation/hemostatic activity,
and reduced fibrinolysis. 116, 117 During sepsis circulating leukocytes release uPA,
tPA, PAI-1 and PAI-2. Which, in conjunction with fibrin deposits and with
inflammatory responses, may cause the persistence of fibrin, thrombosis and
subsequent multiple organ failure.21
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Table 2.3 Pathophysiologic factors that regulate fibrinolysis/thrombolysis.9
Promote
Limit
Plasminogen incorporation into a thrombus via
Fibrin crosslinking by factor XIIIa
fibrin binding
Platelet clot retraction
Low ratio of tPA to plasminogen activator
inhibitor (PAI-1 or 2)
Endothelial cell and macrophage biosynthesis
Low ratio of endothelial surface to thrombus
of tPA and uPA
volume in large vessels
Binding of tPA to fibrin
Efficient inhibition of free plasmin by α2antiplasmin
Enhanced tPA or uPA activity in the presence
α2-antiplasmin impairs plasmin binding to fibrin
of fibrin
Protection of plasmin (bound to fibrin) from α2Binding of α2-antiplasmin to fibrin
antiplasmin binding
Plasmin activation of factor XII
Increased activated protein C decreases PAI-1
activity

2.18.2 Urokinase and Urokinase Receptor in the Vascular
System
Fibrinolysis is initiated in a damaged vessel wall following production of
tissue-type and urokinase-type plasminogen activators by the endothelial cell.118
Increased plasminogen activator expression in the vessel wall facilitates vascular
smooth muscle migration and cell proliferation for vessel healing by initiating a
proteolytic cascade of matrix degradation.118 Angiogenic properties of uPAR are
related to binding of and improving adhesion properties of vitronectin, which is an
important extracellular matrix protein in angiogenesis during vascular remodeling
and repair.31 In normal saphenous veins and internal mammary arteries of
people, tPA, uPA and PAI are minimally expressed in the endothelium, intimal
and medial smooth muscle cells. The uPAR is observed on the endothelium of
normal saphenous vein or internal mammary artery but absent on the smooth
muscle cells.118 A recent study of mouse arteriogenesis suggested that uPA
itself is the most important promoter of leukocytes required for collateral artery
growth. Association of leukocyte infiltration with arteriogenesis is strongly
reduced in uPA-/- but not in uPAR-/- or tPA-/- mice.119
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2.18.3 Urokinase and Urokinase Receptor in Wound Healing
Urokinase and uPAR are important in clot lysis, and the inflammatory,
proliferative and maturation phases of wound healing. During clot lysis, urokinase
is released from the tissues and inflammatory cells. Urokinase cleaves
plasminogen to plasmin which leads to fibrin breakdown.3 In the inflammatory
phase, uPA and uPAR aid in attraction, adhesion and migration of neutrophils
and monocytes into the injured tissue.9 During the proliferative phase, uPA is
important in stimulating the growth of capillaries into the granulation bed through
its angiogenic properties. In the maturation phase, uPA-uPAR complexes
continue to contribute to break down of fibrin in the provisional matrix to allow
fibroblasts to enter and make true extracellular matrix. Urokinase and urokinase
receptor would also aid in epithelialization because of the high affinity for uPAR
to vitronectin, which is important in allowing epidermal cells to interact with the
underlying extracellular matrix.31, 120
In a rat model of tendon healing, uPAR and uPA accumulation in the
healing tendon was regulated hin a time dependant manner. Changes in
concentrations of uPA and uPAR correlated with phases of wound healing. Both
uPAR and uPA expression peaked at day 14 and decreased at day 21 postinjury. 60
2.19 Summary
The fibrinolytic system has many roles both within and outside of the
vascular system. Urokinase is an activator of the fibrinolytic system. Urokinase is
present in parts of the urinary tract of mammals and is excreted in urine. The
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exact purpose of urokinase in urine is unknown but it may prevent obstruction of
the urinary tract by blood clots and fibrin.
Identification and quantification of uPA in the urine of dogs would suggest
that uPA has some role in the health of the canine urinary tract. Localization of
uPA in the prostate of canines may be important since castration prior to urinary
diversion surgery may be beneficial in decreasing post-operative bleeding. Use
of drugs such as ε-aminocaproic acid that competitively inhibit plasminogen
activator substances have been used successfully in people to inhibit uPA and
decrease bleeding; however dosages have not been established in dogs. If uPA
is identified in urine from dogs in significant concentrations, the possibility of
exploring its role in unhealthy dogs and the use of pharmacologic agents in
manipulating its activity can be explored.
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Chapter 3 Hypothesis and Objectives
3.1 Overall goals
This study demonstrated the presence of urokinase (uPA) in canine urine
and quantified it in normal male and female dogs using an ELISA and a
fluorogenic activity assay. This study also demonstrated the presence of
urokinase and urokinase receptor in the tissues of the canine urinary tract, both
male and female, using immunoprecipitation, SDS PAGE / Western Blot Analysis
and immunohistochemistry techniques.
3.2 Hypothesis and Specific Objectives

3.2.1 Hypothesis
1. Urokinase will be present in urine from healthy dogs.
2. Urokinase concentration will be higher in urine from intact male
dogs than intact or neutered female dogs.
3. Urokinase concentration will be higher in urine from intact male
dogs than neutered male dogs.
4. Urokinase concentration will be the same in intact and neutered
female dogs.
5. Urokinase concentration will be similar in urine from intact female
dogs and neutered male dogs.
6. Urokinase and urokinase receptor will be present in the canine
urinary tract.
7. Antibodies directed against human and mouse urokinase will
recognize urokinase and urokinase receptor in the urinary tract and
from healthy dogs.
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3.2.2 Specific Objectives
•

Demonstrate and quantify urokinase in urine from healthy dogs.

•

Demonstrate presence of urokinase-like antigen and urokinase
receptor-like antigen in the urinary tract from healthy dogs.
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Chapter 4 Sample Selection and Preparation
4.1 Sample Populations
4.1.1 Sample Population for Urine Collection
Fifty four client owned dogs presented to the LSU SVM Small Animal
Hospital Companion Animal Surgery Service that met the following inclusion
criteria were used. The dogs were treated according to the regulations of the
Institutional Clinical Protocol Committee. The dogs were divided into four groups:
16 intact males, 15 sterilized males, 9 intact females, 12 sterilized females.
Inclusion criteria:
1. No physical or biochemical evidence of current renal or lower
urinary tract disease (appendix table 1).
2. No antibiotic administration in the previous 2 weeks.
3. Blood and urine samples being taken for reasons other than this
study (appendix table 1).
4. Normal physical exam, complete blood count, serum
biochemistry and urinalysis (appendix table 1).
4.1.2 Sample Population for Urinary Tract Tissue Collection
Eleven dogs were used for tissue collection; 5 intact males, 2 neutered
males, 4 intact females
The following inclusion criteria were used for case selection:
1. Euthanasia for reasons other than urinary tract or renal disease.
2. No gross pathologic signs of urinary tract or renal disease.
Samples were collected at the time of euthanasia.
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4.2 Sampling Technique
4.2.1 Urine Collection
A minimum of 3 ml of voided urine was collected into a clean receptacle
and transferred to 50ml polypropylene tubes (352070, Becton Dickenson,
Franklin Lakes, NJ) for immediate freezing and storage at -75°C. Freezing and
thawing up to five times does not appear to affect urokinase activity.1 The entire
volume of urine collected and the date were recorded for each sample.
A second urine sample was collected from each dog using a cystocentesis
technique. This urine was then transferred using a sterile needle to a sterile
vacutainer tube. Each sample was then plated on blood agar and Maconkey
plates, incubated for 72 hours at 37ºC and evaluated every 24 hours by the
principal investigator for presence of bacterial colony growth.
4.2.2 Urinary Tract Tissue Collection
1. Kidney: A 2 cm X 1cm full thickness wedge of cortex and medulla was
taken from the middle portion of the kidney.
2. Ureter: A 2 cm full-thickness section was taken from the ureter contra
lateral to that of the kidney biopsy.
3. Urinary bladder: A 2 cm full-thickness 2 cm sample section was taken
from the ventral wall.
4. Prostate: A 1 cm X 1 cm wedge was taken from one lobe of the
prostate.
5. Urethra (male dogs): A 2 cm full-thickness section was taken from the
prostatic and penile regions of the urethra.
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6. Urethra (female dogs): A 2cm full-thickness section was taken from the
middle of the urethra.
7. Testicle: A 2 cm full-thickness wedge biopsy was taken from one
testicle.
4.3 Sample Preparation
4.3.1 Urine Preparation
All urine was thawed in the polypropylene storage tubes at room
temperature and concentrated using Amicon Ulltra-15 PLTK Centrifugal Filter
Units with 30kDa membranes (UFC903024, Millipore Corporation, Burlington,
MA) and Amicon Ultra-4 PLHK Centrifugal Filter Units with 100kDa membranes
(UFC810024, Millipore Corporation, Burlington, MA).
Steps in urine preparation and concentration:
1. The urine was centrifuged in the original polystyrene tubes at
2500rpm for 10 minutes to pull down any debris.
2. Cleared urine was transferred to clean polystyrene tubes leaving
the pelleted debris at the bottom of the original tube.
3. The urine was transferred to 100kDa filter units and volume was
recorded.
4. The urine in the 30 kDa filter units was centrifuged at 2500rpm for
45 minutes. This allowed separation of the urine into two fractions.
The fraction containing proteins greater than 30 kDa was retained
in the upper chamber. The fraction containing proteins less than 30
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kDa passed through the filter and was deposited in the lower
chamber.
5. Urine in the upper chamber (with proteins greater than 30 kDa) was
removed, the volume was measured and the urine was placed in
the 100 kDa filter tubes. The urine in the 100kDa filter units was
centrifuged at 2500rpm for 30 minutes. This allowed separation of
the urine into two fractions. The fraction containing proteins greater
than 100 kDa was retained in the upper chamber. The fraction
containing the remaining proteins between 100 kDa and 30 kDa
passed through the filter and was deposited in the lower chamber.
This fraction should contain urokinase which has a molecular
weight of 33kDa in the short chain form and 53kDa in the heavy
chain form.
6. Urine in the lower chamber (with proteins between 30 kDa and 100
kDa) was removed, the volume was measured and the urine was
placed in placed in 1.5ml microcentrifuge tubes (20170.022, VWR
International, Suwanee, GA).
7. Urine samples were frozen at -20°C until evaluation.

4.3.2 Tissue Preparation for Morphological Study
Tissue samples collected from nine dogs (four intact males, two castrated
males and three intact females) were immediately frozen in Tissue-Tek OTC
compound (4583, Sakura Finetechnical Co., Ltd., Tokoya, Japan) and stored at -
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70 ºC for later paraffin embedding or desiccation and processing with RIPA
buffer.
Samples collected from two dogs (one intact male and one intact female)
were placed in formalin immediately for later comparison with the fresh frozen
samples to identify any freezing artifacts.
Paraffin sections (4um) were cut and stained with hematoxylin and eosin
or used for immunohistochemical staining.
4.4 References
1.

Wilson MJ, Ditmanson JD, Sinha AA, Estensen RD. Plasminogen
activator activites in the ventral and dorsolateral prostatic lobes of aging
Fischer 344 rats. The Prostate. 1990;16:147-161.
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Chapter 5 Fluorogenic and ELISA Assays for Urokinase in Urine
5.1 ELISA Assay Introduction
Quantification of proteins in tissues or fluids can be achieved in several
ways. An ELISA can measure both the inactive and active forms of an antigen by
measuring antibody-antigen interaction which is linked to an enzyme which
reacts on a chromogenic substrate. This substrate causes production of a color
change. The color intensity is measured by a plate reader based on the number
of antibody-antigen complexes formed. Success with this method requires
measurable amounts of the antigen of interest.1
The direct ELISA, Indirect ELISA and Sandwich ELISA are the basis of all
ELISAs. 2
The direct ELISA is the simplest. Only one primary antibody is used and
this antibody is directly conjugated with an enzyme. Addition of a substrate
allows visualization of the reaction.2
The indirect ELISA is similar to the direct ELISA except that the antigen is
targeted initially by an unlabelled detecting or primary antibody. An antispecies
antibody, which is bound to a conjugated enzyme, is then added. Addition of a
substrate specific for the enzyme allows detection of the reaction.2
The sandwich ELISA can be subdivided into direct and indirect sandwich
ELISAs. In both the primary antibody is passively attached to a solid phase plate
by incubation in a buffer. After washing away the free antibodies, the antigen of
interest is added and captured by the coating antibodies. For the direct sandwich
ELISA a single antigen-specific antibody with an enzyme label is added; for the
indirect sandwich ELISA, an unlabelled antibody is used followed by a second
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enzyme labeled-antibody. For both sandwich ELISAs, a substrate specific for the
enzyme is added to visualize the reaction.2
Reading of the reactions or measurement of the color produced in the
ELISA is generally performed with the use of a plate reader. The plate reader
contains a spectrophotometer which quantifies the degree of color change
obtained with particular enzyme/chromophore systems. The wavelength must be
set for the absorption maxima of the chromophore. Plates can be read only
qualitatively by the naked eye. A plate reader is required to more able to detect
subtle differences in absorption between wells in the plates and give a
quantitative analysis.2
5.2 ELISA for Urokinase Quantification in Urine
Urokinase is present in tissues and urine of mammals in active and
inactive enzymatic forms.3-6 An ELISA can measure both the active and inactive
urokinase in a sample. ELISA kits for urokinase are available. The antibodies in
these kits are directed towards human and mouse urokinase. We created a direct
sandwich ELISA using antibodies which we had already shown to successfully
bind with canine urokinase in western blot analysis, immunoprecipitation and
immunohistochemistry. (Chapter 6, section 6.6 and chapter 7, section 7.4)
5.2.1 Samples
Fifty-four urine samples were collected from healthy dogs (appendix table
1) and prepared as described in chapter 4, Sample Selection and Preparation.
Each sample was allowed to thaw at room temperature prior to addition to the
sample wells. Thirty-eight samples were run in duplicate (appendix table 3).
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5.2.2 Antibodies, Purified Enzymes and Buffers
•

Primary Coating Antibody - Mouse Monoclonal to mouse uPA – A capture
monoclonal antibody produced in a uPA knockout mouse. IgG fraction
purified by Protein A Sepharose. (H77A10, Molecular Innovations,
Southfield, MI)

•

Secondary Labeled Antibody - Rabbit anti-human uPA IgG fraction, biotin
labeled – Biotin labeled polyclonal antibody (host rabbit). IgG fraction
purified by protein A sepharose. (ASHUPA-GF-BIO, Molecular
Innovations, Southfield, MI)

•

Standard Control Enzyme - Human HMW Urokinase – Prepared from
human urine as the two-chain form. (UPA-HTC, Molecular Innovations,
Southfield, MI)

•

General Buffer - Phosphate Buffered Saline (PBS) – Fisher Gram-Pac
Buffer pH 7.41. (B-82, Fisher Scientific, Fair Lawn, NJ)

•

Blocking Buffer - 2% bovine serum albumin (BSA) (0332-25G, Amerseco,
Solon, OH) in PBS

•

Dilution Buffer - 0.5% BSA (0332-25G, Amerseco, Solon, OH) in PBS

•

Washing Buffer – 0.5% Triton-X-100 (161-0407, Bio-Rad Laboratories,
Hercules, CA) in PBS

•

Substrate – Peroxidase Solution B, H2O2, (50-65-00, KPL, Gaithersburg,
MD)

•

Chromophore – TMB (50-76-01, KPL, Gaithersburg, MD) to interact with
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Horseradish peroxidase enzyme to produce a blue color change in the
ELISA wells
•

Stop Agent - 0.1% H2SO4, when added to the well this stops the reaction
between TMB and H2O2, decreases the pH and changes the reaction to a
yellow color.
5.2.3 ELISA Technique
Standardization: Ninety-six well plates were incubated to determine the

optimal antibody dilution for the ELISA with 100µl of mouse anti-mouse uPA
antibody at 1:250, 1:500, 1:1000, 1:2000, 1:4000 and 1:8000 dilutions at room
temperature overnight. All samples and standards were run in duplicate. After
incubation, 300µl of the blocking buffer was added to the wells for 1 hour at room
temperature. The wells were then washed three times with washing solution and
blotted. Log dilutions of 100µl of pure uPA diluted in PBS were then added to
each of the wells. The standard curve ran from 1 µg to 1 pg in serial log dilutions.
One row was left as blank. The uPA was incubated at room temperature for 2
hours. The wells were again washed three times with washing solution. The
rabbit anti-human uPA antibody was then added at 1:1000 dilutions in a volume
of 100µl at room temperature for 2 hours. The wells were again washed 3 times
with the washing buffer. Streptavidin conjugated to horseradish peroxidase
enzyme was then added at a volume of 100 µl for 30 minutes. The chromophore
was then added for 15 minutes. After this time the reaction was stopped with
0.1% sulfuric acid and the reaction was read in a plate reader at 405 nm.
Urine samples were run in the same manner as described. The dilution of
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the mouse anti-mouse uPA antibody was 1:8000. The uPA standard was diluted
from 1000 ng to 1 ng (figure 5.1).

Figure 5.1 Direct sandwich ELISA for canine uPA. The addition of the substrate H2O2 results in
the following reaction H202 → H20 + Ö. The resultant free oxygen radical reacts with the
chromogen TMB to produce a blue color change. Stopping the reaction with H2SO4 decreases the
pH causing the end color to be yellow.

5.2.4 Problems
The large number of dilutions was required to choose the primary antibody
dilution for the test samples was due to presence of background in the wells.
Ideally one would like to see background readings close to 0 to ensure that
samples with low concentrations of the antigen of interest are not blocked out. In
our case, the background was likely due to the non-specific binding of the rabbitpolyclonal antibody to the mouse-monoclonal antibody. Even with a dilution of
1:8000, some background was still evident; however the level was acceptable
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acceptable without loss of uPA delectability.
5.3 Activity Assays Introduction
Chromogenic and fluorogenic substrates are used to measure only the
active form of the enzyme in question.3-7 Enzymes are proteins which catalyze
most of the chemical reactions in the body. In the case of uPA the activity is
thrombolytic activity.8 The chemical compound upon which the enzyme exerts its
catalytic activity is the substrate.7 Proteolytic enzymes degrade their substrates,
proteins and peptides by hydrolyzing one or more peptide bonds.
5.3.1 Chromogenic Assays
Chromogenic substrates are peptides which react with proteolytic
enzymes causing color changes based on the level of activity.3-6 Chromogenic
substrates are made up of a protecting group, amino acid residue(s), side chain
modification if applicable and the chromophore. The most commonly used
chromogenic substrate for measurement of uPA activity in tissues, plasma and
urine is S-2444 (Chromogenix, MöIndal, Sweden) from Diapharma. The chemical
formula for this compound is <Glu-Gly-Arg-pNa HCl (L-Pyroglutamyl-glycyl-Larginine-p-nitroaniline hydrochloride).62 The reaction is simple:
<Glu-Gly-Arg-pNa

Enzyme→

<Glu-Gly-Arg-OH + pNa

The method for determining activity is based on the difference in
absorbance (optical density) between the pNa formed and the original substrate.
The rate of pNa formation, i.e. the increase in absorbance per second at 405nm,
is proportional to the enzymatic activity and is determined with a
spectrophotometer.62
This substrate has been used to measure uPA activity successfully in
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human urine, however, the method of purification used was gel filtration and the
quantities of urine used were large.3-6 In our study we did not purify the urine but
rather concentrated it using biologic filters to contain molecular weight proteins
between 30 kDa and 100 kDa. This allowed us to decrease the quantity of urine
collected since collection of large volumes of urine from one dog was often
impossible. Filtering the urine did not alter the yellow color of urine. Since the
wavelength used for measuring the reaction with S-2444 and other chromogenic
substrates is 405nm, which is the yellow wavelength; the filtered urine could not
be accurately assessed with this method as the yellow color interfered with the
results.
5.3.2 Fluorogenic Assays
Fluorogenic substrates measure activity along the same principal as the
colorimetric substrates. These substrates contain a fluorophore rather than a
chromophore and cleavage of this fragment is determined by the fluorescent
activity.7 The substrate used to evaluate uPA excites at 360-380nm with
emission at 440-460nm.9 These reactions can also be performed in 96 well plates
however the wells must be have black sides and black or clear bottoms to
prevent interference from neighboring wells. This method can quantify the
concentration of uPA in the urine. The fluorescence activity is compared to a
standard fluorescence curve derived from with known concentrations of pure
human urokinase.
5.4 Fluorogenic Activity Assay for Urokinase Quantification in Urine
The fluorogenic substrate used in our experiment was Urokinase
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Substrate III from Calbiochem. The chemical composition of this substrate is
similar to that of S-2444 with the exception of the end group Glutaryl-Gly-ArgAMC, AMC being the fluorophore. The yellow color of the urine does not interfere
with the fluorescence however urine does contain xanthenes which have
autofluorogenic properties. Fortunately the xanthenes tend to excite at higher
wavelengths than that of uPA activity. To verify lack of interference with our
samples, random samples were run without the substrate at the required
excitation and emission for the Glutaryl-Gly-Arg-AMC reaction. No fluorescent
activity was noted.
5.4.1 Samples
Urine samples were collected and processed as described in chapter 4,
Sample Selection and Preparation. Each sample was allowed to thaw on ice to
4ºC prior to addition to the sample wells. Fifty samples evaluated in the assay.
5.4.2 Substrates and Buffers
•

Fluorescence Buffer – 6g Tris, 7.9g TrisHCL adjusted to pH 7.5-7.7; 1g
polyethylene glycol(6000); 5.8g Sodium Chloride; 3.78g D-Mannitol, in one
liter of distilled water.

•

Substrate – Urokinase Substrate III, Fluorogenic, Z-Gly-Gly-Arg-AMC, HCl
(672159, Calbiochem, San Diego, CA)

•

Enzyme - Human HMW Urokinase – Prepared from human urine as the
two-chain form. (UPA-HTC, Molecular Innovations, Southfield, MI)
5.4.3 Fluorogenic Assay Technique

The technique used was modified from a technique described by Enzyme
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Figure 5.2 Schematic representation of fluorescence assay for uPA using Urokinase Substrate III.
When the Urokinase Substrate III is added to the uPA in the fluorescence buffer, the active uPA
cleaves the AMC group from the Urokinase Substrate III. The AMC is excited at a wavelength of
360/380 nm and the fluorescence is emitted at a wavelength of 440/460 nm. The diagrams
represent one well in the 96 well plate. Activity is read at time 0 and 5 minutes.

Systems Products.10 We modified volume of urine to allow samples to be run in
96 well Microplat Standard SUR plates (BD 353293, Becton Dickenson, Batavia,
IL)
All samples were run in triplicate and all reactions were performed at
approximately 4ºC. Urokinase standard curves were run with each plate using
pure human uPA in serial dilution starting at 2 µg and ending at a 1:64 µg
dilution. With the plates on ice, 182µl of the fluorogenic buffer was added to each
test well. Eight microliters of pure uPA or sample was then added to each well.
This mixture was allowed to equilibrate for 15 minutes on ice. Following the
equilibration, 8 µl of the Urokinase Substrate III was added to each well. The
plate was then placed in a Fluorescence Plate Reader and agitated for 6
seconds. The plates were read at time 0 and 5 minutes at excitation maxima of
360/40 and emission maxima of 460/40nm (figure 5.2). Standard curves were
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generated for each plate and concentration based on activity was translated from
the standard curve (appendix figure 1).
5.5 Statistical Analysis
The urokinase concentration and the urokinase enzymatic activity (EA)
was corrected for the volume of concentrate:original volume of urine by
multiplying the concentration of the tested sample by the original
volume/concentrated volume. The urokinase concentration and the enzymatic
activity were expressed as units/mg Cr /uL urine.
The urokinase concentration and the enzymatic activity was also adjusted
for the concentration of creatinine in the urine. The creatinine-adjusted urokinase
concentration and the enzymatic activity were then expressed as units/mg Cr /mL
urine.
The urokinase concentrations and the creatinine-adjusted urokinase
concentrations were plotted and the distribution of the data visualized and
described. Normality was tested using the Shapiro-Wilk statistic with the null
hypothesis of normality rejected at p<0.05. Since all data was not normally
distributed, comparisons were made between gender (male vs female) and
between sexual status (male neuter, male intact, female spayed, female intact)
using the Wilcoxon-rank sum test and the Kruskall-Wallis test, respectively.
Significance was determined at p<0.05.
The linear correlation between the urine creatinine concentration and the
urokinase concentration was explored using Spearman’s rank test. The
Spearman correlation coefficient rho (ρ) is reported. Moderate correlation was
considered if ρ > 0.65; marginal correlation if ρ > 0.40.
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SAS (PROC CORR, PROC NPAR1WAY, PROC UNIVARIATE) was used
for the analysis. (SAS v 9.1, SAS Institute, Cary, NC).
5.6 Results
Urokinase concentration - The distribution for the urokinase concentration
and the creatinine-adjusted urokinase concentration for each group was skewed
to the right and the null hypothesis of normality was not rejected, except for the
urokinase concentration of females and castrated males (figs 5.3 and 5.4, tables
5.1 and 5.2 and appendix table 3). There was no significant difference between
males and females or among sexual status for urokinase or creatinine-adjusted
urokinase concentrations.
There was poor to marginal correlation between the creatinine
concentration and the urokinase concentration in the urine from male dogs
(ρ=0.24), male castrated dogs (ρ=0.49) and female dogs (ρ=0.49). There was
moderate correction for female spayed dogs (ρ=0.67) (fig 5.5). When all female
dogs were grouped together, the correlation was marginal (ρ=0.36).
EA concentration – The distribution for the EA and for the creatinineadjusted EA for each group was heavily skewed to the right and the null
hypothesis of normality was not rejected (figs 5.6 and 5.7 and appendix table 2)
5.7 Discussion
Urokinase is present in urine of healthy dogs in small but measurable
quantities. The ELISA assay measured urokinase in both the active and inactive
state. The fluorescent assay measures only active uPA in the urine.
Sampling technique created additional work in this experiment because
we used variable volumes in our samples and concentrated them to variable
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Figure 5.3 ELISA assay of canine urine versus dog groups, ng urokinase/µl urine

Figure 5.4 ELISA assay of canine urine versus dog groups, ng urokinase/mg creatinine/µl urine
Table 5.1 Standard Deviation, coefficient of variation, median and quartiles for volume corrected
ELISA results

Mean
Std Deviation
Coeff of Variation
Minimum
Lower Quartile
Median
Upper Quartile
Maximum

Female
381.49
269.82
70.73
- 53.89
199.71
305.15
617.58
825.39

Female Spayed
1007.10
924.19
91.77
114.87
329.63
612.38
1652.52
2944.16
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Male
890.44
928.41
104.26
81.43
185.42
395.19
2030.64
2524.30

Male Castrated
366.41
272.55
74.38
-21.18
106.91
379.21
598.48
799.36

Table 5.2 Standard Deviation, coefficient of variation, median and quartiles for volume and
creatinine corrected ELISA results.

Mean
Std Deviation
Coeff of Variation
Minimum
Lower Quartile
Median
Upper Quartile
Maximum

Female
14.12
9.93
70.38
-2.42
6.44
15.06
19.89
34.67

Female Spayed
63.85
66.35
103.92
7.56
17.48
45.15
68.26
226.29

Male
59.59
92.98
156.03
3.69
9.64
24.89
69.31
386.90

Male Castrated
32.39
27.47
84.81
-1.65
10.63
23.09
55.30
86.30

Figure 5.5 Fluorescent Activity assays of canine urine versus dog groups, emission activity (EA)
of urokinase / mg creatinine/ µl urine

Figure 5.6 Correlation between creatinine levels and urokinase concentrations in female spayed
dogs.
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Figure 5.7 Fluorescent Activity assays of canine urine versus dog groups, emission activity (EA)
urokinase / µl urine
Table 5.3 Standard Deviation, coefficient of variation, median and quartiles for volume corrected
fluorescent assay results
Mean
Std Deviation
Coeff of Variation
Minimum
Lower Quartile
Median
Upper Quartile
Maximum

Female
0.001
0.001
158.31
0
0
0
0.001
0.003

Female Spayed
0.001
0.002
176.02
0
0
0
0.001
0.005

Male
0.001
0.002
173.48
0
0
0
0.002
0.007

Male Castrated
0.001
0.002
167.67
0
0
0
0.001
0.006

Table 5.4 Standard Deviation, coefficient of variation, median and quartiles for volume and
creatinine corrected fluorescent assay results.
Mean
Std Deviation
Coeff of Variation
Minimum
Lower Quartile
Median
Upper Quartile
Maximum

Female
0.03
0.06
188.24
0
0
0.003
0.04
0.19

Female Spayed
0.07
0.12
166.06
0
0
0
0.13
0.34

Male
0.10
0.18
187.09
0
0
0
0.09
0.65

Male Castrated
0.07
0.10
146.21
0
0
0
0.001
0.32

volumes. Doing this required that we calculate concentration factors for each
urine sample and apply this number to the values obtained in each assay prior to
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evaluation. This method was necessary in our study because we did not have
any prior knowledge of the expected concentration of urokinase in canine urine.
We collected maximum volumes in an attempt to ensure we did not miss
urokinase because the volume was too small. If the expected concentration of a
protein is known per unit of volume, one can start with and end with equal
volumes of the urine or other sample to eliminate this step. With the results from
the data we collected, in future studies we could use uniform start volumes of at
least 3 mls and end volumes of at least 150 µl.
Urokinase activity has been measured directly by means of chromogenic
substrates such as S-2444 which measure the amidolytic determination of
urokinase activity in purified preparations and urine.4 This method requires a
colorless sample as the yellow color of xanthenes in the urine interferes with the
spectrum for measuring color change in the chromogen of S-2444 and other
similar compounds. To purify the urine for this technique, gel chromatography is
used to recover only the purified urokinase from samples. This requires large
volumes of urine which are difficult to collect from dogs. This problem led us to
instead choose the fluorescent assay as a means of measuring the active uPA in
the urine samples collected from the dogs.
The technique used was adapted from a technique described by Enzyme
Systems Products.10 The original technique was run in larger wells with larger
volumes of buffer, enzyme and sample and was intended for use in plasma. To
ensure that the autofluorescent properties of urine did not interfere with the
sample reading urine samples were placed in wells without enzyme. They
showed no fluorescence. The chemical, Z-Gly-Gly-Arg-AMC, HCl, has affinity for
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urokinase as was demonstrated by its activity on pure urokinase in the standard.
This chemical has also been used for evaluation of urokinase activity in plasma
but not in urine.
Results In the fluorescence assay showed high variability, as
demonstrated by the slopes of the standard curves. The variable readings in our
assay could be the result of many issues. Using urine which had not been
dialyzed by gel filtration left a sample which was still high in organic salts. This
may have interfered with the reaction between the urine and the fluorescent
substrate. The sample volumes placed in each well were very small, 8µl. This
leads to increased risk of error by the person filling the wells. Use of a
multichanel pipette would have decreased that risk but multichanel pipettes are
not made to handle volumes smaller than 10 µl. Errors made with small volumes
include leaving the sample on the side of the well, and not completely emptying
the pipette when adding the sample. Either incident would dramatically change
the result when the activity is volume dependant. A third area for error was also
due to the fact that a multichanel pipette was not used. This assay is time
sensitive, with measurements taken at time 0 and 5 minutes. Although we tried
to minimize the error associated with this problem by plating multiple plates with
fewer samples, this probably also factored into the final values. All of these
sources of error affected the results of our standard curves resulting in a lot of
variability from plate to plate. This made comparison of values from plate to plate
using the generated standard curves impossible. To enable comparison of all the
plates we transformed the standard curves using a global fit standard curve,
which averaged the readings of all the standard curves creating to make one of
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best fit, thereby creating an artificial curve. The fluorogenic readings from each
plate were then plotted along this new standard curve to extrapolate
concentrations for each sample. In an ideal situation one would be able to use
the same standard curve for every plate because the protocol would have very
little variance from run to run. Methods for improving the variability in our assay
would improve our results. Larger volumes of urine and substrate would help to
decrease the effects of dilution or concentration if the volume varied slightly
between wells. In most assays the minimum repeated volume is 50 µl, which
decreases the risk of pipette induced error. Using larger volumes of the substrate
also increases the cost of the assay considerably. Use of a multi-channel pipette
to load the samples and substrate would decrease the time involved and the
variability between wells. Switching to 24 well plates would allow larger volumes.
All of these things together would decrease the variation considerably and maybe
allow a repeatable standard curve and comparison of values without transforming
the data.
Due to the extreme variability in results I do not feel that the
concentrations obtained in the fluorescence activity assay could be taken as
accurate concentrations (appendix table 2). I do feel that for those samples in
which a value was obtained, that value is a measure of the urokinase activity in
the volume of urine placed in the well. The comparison between groups is also of
limited value. There may be differences between the groups that are not evident
because the higher values in the actual plate would have been lowered to fit the
global standard and the lowest values would have been raised. This results in
less difference between the highest and lowest values. If there were a large
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difference in activity between the groups we may still have seen a difference
despite the large variation in our samples due to pipette error.
The ELISA assay appeared to produce less variable results (appendix
table 3), however, the amount of background in the ELISA was higher than
desired. The high background was likely due to the non-specific binding of the
rabbit-polyclonal antibody to the mouse-monoclonal antibody. This could be
further decreased by either increasing the dilution of secondary labeled antibody
to 1:2000 or further, or by passing the rabbit antibody through a mouse
immunoglobulin column to remove the mouse specific immunoglobulins.
The antibodies chosen for the ELISA were tested in the SDSPAGE/western blot assays. Both antibodies worked in the nonimmunoprecipitated and immunoprecipitated urine samples, suggesting that the
mouse anti-mouse antibody and the rabbit anti-human antibody for uPA
recognize uPA-like protein in the urine and tissues of healthy dogs. The choice of
a 1:1000 dilution for the rabbit antibody was based on the use of this dilution in
the Western blot assay. In general the dilution in a Western blot will also work
well in an ELISA using the same antibodies.
One concern in the ELISA assay and the method of concentration used to
prepare the urine samples is retention of organic salts in the urine samples.
These salts can interfere with binding of the antibody to the protein resulting in
the appearance of lower concentration of uPA than is actually present. This may
have been a problem with our samples. The relationship between the ELISA
concentrations and the fluorescent concentrations cannot be compared directly;
however, one would expect that the fluorescent readings would all be lower than
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the ELISA readings because the fluorescent readings are only measuring active
uPA. The samples evaluated were consistently lower in the ELISA, once
corrected for volume and urine creatinine, than the comparable corrected
fluorescent readings. This would suggest that salts may have a major impact on
binding in the ELISA assay.
Use of a sandwich ELISA allowed us to measure concentration of active
and inactive urokinase. Again, I am unsure of whether the absolute concentration
within the samples is accurate. I do believe that the relative concentrations
between samples are of value as the procedure had less room for operator error
than the fluorescent assay. The volumes were much larger using 100 µl for each
sample and a multichanel pipette was used to apply all the antibodies and
stopping agents.
Another issue which may have an impact on determining absolute
concentrations of uPA in urine for comparison between animals is the question of
relationship between concentration of urine and uPA. Using creatinine is an
acceptable method of correcting for concentration when evaluating urea and uric
acid because the proteins are all excreted in the urine at a constant rate. We do
not know if uPA and creatinine are excreted in a comparable rate or ratio. Some
papers do correct for urine concentration using creatinine and express the
concentration of uPA as a function of mg/ml of creatinine.1, 11 Other papers
express the concentration of uPA in mg/ml using only a volume correction for
their calculation.12, 13 This tends to be used more often in healthy subjects or
when uPA activity is being evaluated as opposed to total concentration. To use
only a volume correction the assumption must be made that uPA is excreted at a
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constant rate per milliliter of urine produced. This may be the case in a normal
healthy person; however, one study has shown that diuresis does decrease the
uPA concentration in urine.14 This would indicate that, at least in extreme cases
of diuresis and filtration activity by the kidney, uPA excretion into the urine does
not match the normal concentration produced per milliliter of urine.14, 15 In the
case of renal disease the concentration of uPA in excreted urine, as compared to
healthy people, has been shown to be higher in people with renal disease of
various types.13 Some other papers suggest that uPA excretion may be
decreases in renal disease due to increased PAI-1 activity in the kidney.16, 17
Many of the dogs presented to the Louisiana State University Veterinary
Teaching Hospital and Clinic are stressed, have had long car rides or may have
been fasted if they were scheduled for surgery the day they presented. This may
have affected their normal hydration status and in turn have affected our
samples. Collecting samples in a more controlled manner would eliminate this
consideration. This, however, is often not a practical solution when trying to
obtain large numbers of samples.
Statistically there may be a weak correlation between creatinine and uPA
noted only in female spayed dogs. Whether creatinine is appropriate to use as a
correction factor for uPA would depend on whether its excretion is proportional to
that of uPA. Creatinine is excreted at a constant rate in the urine due to muscle
metabolism. It appears that uPA is excreted in healthy people at a constant rate
per volume of urine. However, if the same person undergoes diuresis, the
concentration of uPA per milliliter of urine decreases.14 Obviously in a clinical
setting these factors would be impossible to control. This is most likely why
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researchers use creatinine is used to correct for concentration differences
between samples.
When evaluating the statistical differences between gender and sexual
alteration, there is a large amount of overlap between the groups. With the small
sample numbers we cannot state that there is a significant difference between
the groups, however, evaluation of the distribution within the scatter plots shows
evidence of extreme outliers in the male intact and female spayed groups when
uPA concentration is corrected for creatinine. If we had a larger sample size, this
may reveal that these points are not actually outliers but the tail of the
distribution.
In conclusion, uPA is present in the urine of healthy dogs in very small but
measurable quantities. It appears to be present in both the active and inactive
form. At this time, differences in uPA excretion based on gender and sexual
alteration appear to be not significantly different. This may change as the assays
are improved and with larger sample sizes. The assays described are not refined
enough to give accurate concentrations of uPA in the urine. Further work would
enable both techniques to be useful in a research setting to provide information
about uPA concentration in urine and possibly even in a clinical setting.
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Chapter 6 Urokinase and Urokinase Receptor Identification with
SDS PAGE, Western Blot and Immunoprecipitation
6.1 Introduction
Proteins in tissues or fluids can be identified by separating them based on
molecular weight. Proteins can be separated for identification by sodium dodecyl
(lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).1 A molecular
weight marker and control sample containing the targeted protein allow
identification of the molecular weight of samples tested in this manner. Migration
of the proteins through the gel, compared to molecular weight markers and
controls, identifies the protein. Western Blot allows visualization of a protein band
based on its recognition by an enzyme-labeled antibody in an ELISA-type
reaction.2 The protein band is then compared to the molecular weight marker
and control sample.
6.2 SDS-PAGE
Sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis utilizes
an anionic detergent (SDS) to coat a sample of proteins with uniform negative
changes to the protein will migrate through a gel towards a cathode. SDS has a
long hydrophobic tail that binds quantitatively to the hydrophobic side-chains of
amino acids of proteins.1 SDS binds at a constant ratio of 1.4g of SDS to 1g of
polypeptide. The larger the molecule, the more SDS binds.
Proteins possess amino acid chains which are either positively or
negatively charged. Electrophoresis separates proteins by moving them across a
gel towards a positive charge. The SDS has a high negative charge giving
proteins within a sample an equal negative charge.1
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Protein tertiary structure also influences migration through a gel. If two
proteins have equal mass, the protein with a more linear structure will traverse
the gel more slowly due to the greater resistance offered by its length. Protein
tertiary structure is formed by the opposing electrical charges on the amino acid
chains. Binding of SDS to the amino acid chains removes the opposing electrical
charges resulting in unfolding of the protein. 2-mercaptoethanol or dithiothreitol
added to the SDS causes disruption of disulphide bonds which also hold the
protein in its native physical form. Removal of both electrostatic and the disulfide
bonds from a protein sample results in all proteins within the sample becoming
uniformly linear and movement through the gel.1
Polyacrylamide gel is a semisolid matrix of acrylamide chains cross-linked
to create a porous gel. The percent of acrylamide used depends on the size of
the protein being identified. The porosity of that gel is determined by the length of
the acrylamide chains and the degree of cross-linking. The length of the
acrylamide chains is determined by the concentration of acrylamide in the
polymerization reaction used to make the gel (3.5%-20%). The more
concentrated the acrylamide, the longer the resulting acrylamide chains and the
denser the gel. The denser the gel the more difficult it is for larger proteins to
move though.3 A 7.5% acrylamide gel was selected for identification of uPA since
uPA is relatively small molecule and a previous study had shown success with
this concentration of acrylamide. 4 Other experiments used a 10% acrylamide gel
for identification of both uPA and uPAR.5, 6
A gel can be set up as continuous or discontinuous (figure 6.1). Use of
different buffers is required to create the gel and to fill the running tank. A
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continuous system has only one separating gel and uses the same buffer in the
tank and the gel. We used a discontinuous system with a large pore nonrestrictive gel (stacking gel) layered on top of a separating gel (resolving gel).
The discontinuous system has superior resolution for protein separation and
visualization of protein bands over the continuous system.1

Figure 6.1 SDS-PAGE gels, continuous and discontinuous arrangement

6.3 Western Blot
Western Blot (a.k.a. immunoblot) identifies a protein from a mixture of
proteins based on a specific antigenicity towards a known antibody in an ELISAtype reaction. This also identifies the molecular weight of the protein as
compared to the visual molecular weight marker because it allows visualization of
the protein band.2 The protein bands separated using SDS-PAGE are transferred
to a solid membrane (nitrocellulose or polyvinylidene) via an electric current
applied across the gel and membrane (figure 6.2). The current moves the
separated negatively charged proteins through the gel, onto the membrane. The
membrane is the medium for the ELISA-type reaction.7 Following transfer the
membrane is non-specifically blocked with a protein solution to prevent sites
which do not contain the targeted blotted protein from binding with antibody. This
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non-specific binding would give false positive results and/or cause background
reaction.
The membrane, with the transferred proteins, is incubated in a solution
containing a primary antibody towards the targeted protein.7 The solution of
primary antibody also contains a protein solution such as non-fat dried milk,
casein or bovine serum albumin. If the targeted protein is on the membrane the
primary antibody in the solution will bind with that protein. Following incubation
with the primary antibody, unbound antibody is washed away and a secondary
antibody labeled with an enzymatic marker is added to the membrane. This
secondary antibody is directed towards the species the primary antibody was
raised in, creating a sandwich type effect. The reaction is visualized by adding a
substrate to the enzyme marker on the secondary antibody. This may be a color
reaction or a chemiluminescent reaction depending on the substrate (figure 6.3).7

Figure 6.2 Transfer of proteins from SDS-PAGE gel to polyvinylidene membrane.
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Figure 6.3 Western Blotting Procedure for uPA and uPAR in canine urine and tissue.

6.4 SDS-PAGE and Western Blot for Urokinase and Urokinase Receptor

6.4.1 Samples
Pooled fresh frozen kidney, testicle and prostate and concentrated frozen
urine from healthy dogs were examined. Samples of urine were chosen at
random from the 54 urine samples collected (Chapter 4, Sample Selection and
Preparation). Samples selected were from Male intact #7 and #4 and female
spayed #9 and #7 and an unknown urine sample.
Tissue samples were manually crushed using a Dounce tissue grinder.
Samples were suspended in RIPA buffer (MFCD2100484, Sigma-Aldrich, St.
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Louis, MO) at 4ºC until a homogenous substance remained. The supernatant
was then transferred to polypropylene screw cap micro tubes (72.694, Sarstedt
AG & Co., Newton, NC) and frozen at -20 ºC for later analysis then thawed prior
to SDS-PAGE. Previously concentrated urine that was frozen in 1.5ml
microcentrifuge tubes (20170.022, VWR International, Suwanee, GA) was
thawed at room temperature prior protein separation by SDS-PAGE.

6.4.2 Antibodies, Purified Enzymes and Buffers
•

Monoclonal Antibody against Mouse uPA – A capture monoclonal
antibody produced in a uPA knockout mouse. IgG fraction purified by
Protein A Sepharose. (H77A10, Molecular Innovations, Southfield, MI)

•

Monoclonal antibody against human urokinase B-chain – A murine IgG1
monoclonal antibody directed against a B-chain epitope of human
urokinase, near the catalytic site. Reacts with free and receptor bound,
single and two chain (HMW) urokinase and the B-chain (33kDa) fragment.
(3689, American Diagnostica Inc., Stamford, CT)

•

Rabbit anti-human uPA IgG fraction, biotin labeled – Biotin labeled
polyclonal antibody (host rabbit). IgG fraction purified by protein A
sepharose. (ASHUPA-GF-BIO, Molecular Innovations, Southfield, MI)

•

Monoclonal antibody against human uPA receptor (CD 87) – A murine
monoclonal antibody, subclass IgG2a, recognizing the human urokinase
receptor. It binds with both unoccupied and occupied uPAR, to soluble
uPAR and intracellular uPAR of both normal blood cells and tumor cells.
(3936, American Diagnostica Inc., Stamford, CT)
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•

Peroxidase conjugated Affinity-purified Anti-Mouse IgG (H&L) (Goat) (Min
X Human Serum Proteins). (611-1322, Rockland Immunochemicals Inc.,
Philadelphia, PN)

•

Peroxidase conjugated Affinity purified Anti-Rabbit IgG (H&L) (Goat) (Min
X Human Serum Proteins). (611-1322, Rockland Immunochemicals Inc.,
Philadelphia, PN)

•

Active Mouse Urokinase, HMW – Active two-chain HMW mouse
urokinase, recombinant produced in insect cells. (MUPA, Molecular
Innovations, Southfield, MI)

•

Human HMW Urokinase – Prepared from human urine as the two-chain
form. (UPA-HTC, Molecular Innovations, Southfield, MI)

•

Lower Gel Buffer – 181.7g Tris, 5.0g SDS to 750ml distilled water, adjust
pH to 8.8 with concentrated HCl, then bring to 1000ml. Refrigerated.

•

Upper Gel Buffer – 30.3g Tris, 2.0g SDS to 350ml distilled water, adjust
pH to 6.8 with concentrated HCl, then bring to 500ml. Refrigerated.

•

SDS Running Buffer – 60.6g Tris, 288.0g Glycine, SDS 20.0g in 2 liters of
distilled water. Store at room temperature. Diluted 1:10 with distilled water
before using.

•

Tris Buffered Saline (TBS) – 10 mM Tris pH 7.5, 150 mM NaCl in 1000 ml
distilled water.

•

Western Transfer Buffer – 0.2g SDS, 5.8g Tris, 2.8g Glycine, 150ml
MeOH, 850ml distilled water. Refrigerate.

•

Stacking Gel – 1.25ml upper gel buffer, 2.95 ml distilled water, 0.8ml of
30% acrylamide(EM Science, Darmstadt, Germany) , 15µl 10%
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Ammonium Persulfate (17874, Pierce Chemicals, Rockford, IL), 5µl TMED
(17919, Pierce Chemicals, Rockford, IL)
•

7.5% SDS PAGE Resolving Gel – 8ml lower gel buffer, 13.25ml distilled
water, 10.5ml 30% acrylamide (EM Science, Darmstadt, Germany), 50µl
10% Ammonium Persulfate (17874, Pierce Chemicals, Rockford, IL), 25µl
TMED (17919, Pierce Chemicals, Rockford, IL)

6.4.3 SDS PAGE Procedure
The SDS-PAGE gel and buffers were prepared as described above in
quantities sufficient to create to gels in a BioRad Minigel II apparatus (170-3056,
Bio-Rad, Hercules, CA). This is consistent with the procedure described by
Laemelli. 8 Protein in both tissue and urine samples were denatured by boiling at
100ºC. Four microliters of 4X SDS Sample Buffer (70607, Novagen, Madison,
WI) was added to 20 µl of denatured sample and applied to the SDS gel (10cm
resolving gels of 7.5% acrylamide and 2cm stacking gels of 4% acrylamide). The
samples were subjected to electrophoresis at room temperature at 100mV for 2
hours or until the dye reached the bottom of the gel. Perfect Protein™ HRP
Western Blot (69078-3, Novagen, Madison, WI) molecular weight marker or
Rainbow Markers (RPN800, Amersham Biosciences, Buckinghamshire, England)
molecular weight marker, were run in the first lane beside the samples to enable
identification of the molecular weight of each protein band.

6.4.4 Western Blot Procedure
Separated proteins were transferred from the SDS gel to Polyvinylidene
Fluoride membranes (BioTrace PVDF, 66543, Pall Corporation, Pensacola, FL)
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for Western Blot analysis using western transfer buffer. Protein transfer was
performed in a Bio Rad Mini Gel Transfer (170-3056, Bio-Rad, Hercules, CA)
western blot apparatus over one hour at 100mV. The polyvinylidene membrane
was then incubated with the primary antibody at 1:1000 dilutions in a 4% non-fat
dry milk powder reconstituted in TBS solution for 16 hours at 4ºC. For detection
of urokinase we used mouse anti-mouse uPA (H77A10, Molecular Innovations),
mouse anti-human uPA (3689, American Diagnostica Inc.) and rabbit anti-human
uPA (ASHUPA-GF-BIO, Molecular Innovations) as the primary antibodies. For
urokinase receptor detection we used a mouse anti-human uPAR antibody
(3936, American Diagnostica Inc.) as the primary antibody.
The following morning the membrane was washed 3 times, (30 minutes
each), with the 4% non-fat skim milk solution at room temperature. Following
washing, the membrane was incubated at room temperature for 2 hours, with a
secondary antibody (goat-anti-mouse or goat-anti-rabbit dependant on the
species in which the primary antibody was raised) labeled with a
chemiluminescent tag at a 1:5000 dilution. The membrane was again washed 3
times (30 minutes each) with a 1% non-fat dry milk solution. The results were
visualized using Western Lightning Chemiluminescence Reagent (NEL101,
PerkinElmer Life Sciences, Boston, MA) on Fuji Medical X-ray film, Super RX
(91454, Tokyo, Japan).
6.4.5 Problems
Two main problems were encountered during our SDS-PAGE and
Western Blot experiments. The first was non-specific binding of antibody to the
polyvinylidene membrane causing high background (dark background
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precipitation) at the time of development of the films. This was resolved by using
a lower primary antibody concentration at 1:1000 and secondary antibody
concentration at 1:5000 which lowered the non-specific binding. The membrane
was blocked with the 4% casein solution between the first and second antibody
incubations for three 45 minute applications. This blocking also aided in
prevention of non-specific binding to the polyvinylidene membrane. Use of film
specifically intended for Western Blot analysis also reduced in background.
The second problem was faint or absent signal in our test lanes for
concentrated urine samples and testicle and prostate samples. This was
postulated to be due to low concentrations of uPA in the samples and was
resolved by using immunoprecipitation of the sample prior to SDS-PAGE.
6.5 Immunoprecipitation
Immunoprecipitation is the interaction between a protein and a specific
antibody which allows the proteins to be removed from solution and examined for
quantity or physical characteristics such as molecular weight or isoelectric point.9
Antibody-protein complexes are removed from solution by adding an insoluble
form of an antibody binding protein such as Protein A, Protein G or combination
Protein A/G, rather than depending on spontaneous formation of insoluble
antigen-antibody complexes. This makes determination of an optimal antibody
dilution favoring spontaneously occurring immunoprecipitates unnecessary.
Analysis of the immunoprecipitate is usually via electrophoresis.9 The
choice of immobilized antibody binding protein depends on the species the
primary antibody was raised in. The strength of the interaction between a
monoclonal antibody and Protein G or Protein A is important factor in the
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decision of which to use. These interactions have been evaluated and published.
The success of immunoprecipitation depends on the affinity of the primary
antibody for the targeted protein as well as for Protein A or Protein G. In this
study a combination Sepharose bead with both Protein A and Protein G was
used.
The simplified procedure is as follows9 (figure 6.4):

Figure 6.4 Immunoprecipitation of uPA or uPAR using Protein G/A Sepharose beads

1. An antibody is added to a mixture of proteins which binds specifically
to the targeted protein during an incubation period.
2. The antigen-antibody complex is absorbed from the solution through
addition of an immobilized antibody binding protein such as Protein ASepharose beads and this solution is incubated.
3. The solution is centrifuged and the antigen-antibody complex settles to
the bottom of the tube, attached to the Sepharose beads, in the form of
a pellet.
4. The supernatant is removed from the tube, leaving the pellet behind.
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5. Liberation of the targeted protein can be achieved by boiling the pellet
in the presence of SDS. This destroys the bond between the primary
antibody and the protein, freeing the denatured protein.

6.5.1 Samples
For immunoprecipitation 200µm of pooled fresh frozen kidney, testicle and
prostate and concentrated frozen urine from healthy dogs were examined.
Samples of urine were chosen at random from the 54 urine samples previously
collected (Chapter 2, Sample Selection and Preparation. Samples selected were
from female spayed #7 and an unmarked urine sample.

6.5.2 Immunoprecipitation Procedure
Both tissue and urine samples were incubated with or without 2µm of antihuman uPA antibody at room temperature for 2 hours. Samples without antibody
were used as controls. For uPA detection we used mouse anti-mouse uPA
(H77A10, Molecular Innovations) and mouse anti-human uPA (3689, American
Diagnostica Inc.). For urokinase receptor detection we used a mouse anti-human
uPAR antibody (3936, American Diagnostica Inc.).
The antibody complexes were precipitated by adding Protein G
PLUS/Protein A-Agarose Sepharose beads (IP05, Calbiochem, San Diego, CA)
and incubating for 1 hour at room temperature. The beads were washed 3 times
using Tris Buffered Saline at 4 ºC and the antibody-protein complexes were
separated from each other and the Sepharose beads by boiling at 100 ºC for 3
minutes. The resulting solution containing the targeted protein was separated
using SDS PAGE and evaluated using the western blot technique as described
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previously. Negative controls contained the antibody alone without the tissue
lysate. Perfect Protein™ HRP Western Blot (69078-3, Novagen, Madison, WI)
molecular weight marker or Rainbow Markers (RPN800, Amersham Biosciences,
Buckinghamshire, England) molecular weight marker, was run in the first lane
beside the samples to enable identification of the molecular weight of each
protein band.
6.6 Results

6.6.1 Urokinase without Immunoprecipitation
All samples were evaluated for molecular weight by comparing the
generated proteins bands with Perfect Protein™ HRP Western Blot (69078-3,
Novagen, Madison, WI) molecular weight marker or Rainbow Markers (RPN800,
Amersham Biosciences, Buckinghamshire, England) molecular weight marker,
which was run in the first lane beside the samples. Negative controls contained
lanes without the targeted antigen. Incubation of kidney tissue lysate with both
the mouse anti-mouse antibody and the mouse anti-human antibody produced a
strong band at approximately 50kDa molecular weight (figure 6.5). A second
western blot evaluating the testicle, prostate and kidney lysates demonstrated a
band at approximately 50 kDa and at 30 kDa. The sample was run with a pure
sample of uPA, with known high molecular weight and low molecular weight
forms of uPA in the purified enzyme, which produced bands at the same
molecular weight as the tissue proteins (figure 6.6)

6.6.2 Urokinase Receptor without Immunoprecipitation
All samples were evaluated for molecular weight by comparing the
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Figure 6.5 Western Blot showing urokinase bands at approximately 50 kDa molecular weight.
Samples are of concentrated urine from healthy dogs. PP, Perfect Protein™ HRP Western Blot
(69078-3, Novagen) molecular weight marker; MI, mouse anti-mouse uPA (H77A10, Molecular
Innovations); AD, mouse anti-human uPA (3689, American Diagnostica Inc); #7, unk, F, random
urine samples; kDa, molecular weight in kilodaltons.

Figure 6.6 Western Blot showing urokinase bands at approximately 50 and 30 kDa molecular
weight. (Rainbow Markers) Samples were run with a known control of pure human urokinase
which contains high molecular-weight uPA and low molecular-weight uPA. Samples are from
desiccated prostate, kidney and testicle from a male intact dog (Male #4). kDa, molecular weight
in kilodaltons.

generated proteins bands with Rainbow Markers (RPN800, Amersham
Biosciences, Buckinghamshire, England) molecular weight marker which was run
in the first lane beside the samples. The samples evaluated were from
desiccated prostate, kidney and testicle from the tissue sample group, male dog
# 4 (appendix table 8). Boiled prostate, kidney and testicle samples incubated
with the mouse anti-human uPAR antibody generated 2 protein bands. One band
is at approximately 55 kDa, which is quite light, and another darker band at
approximately 35 kDa (figure 6.7).
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Figure 6.7 Western Blot showing uPAR protein bands at 55 kDa and 35 kDa. (Rainbow Markers)
Samples were run in SDS-PAGE on the same gel as figure 6 which contains a known control of
pure human urokinase. Samples are from desiccated prostate, kidney and testicle from a male
intact dog (Male #4). kDa, molecular weight in kilodaltons.

6.6.3 Urokinase with Immunoprecipitation
All samples were evaluated for molecular weight by comparing the
generated proteins bands with Perfect Protein™ HRP Western Blot (69078-3,
Novagen, Madison, WI) molecular weight marker or Rainbow Markers (RPN800,
Amersham Biosciences, Buckinghamshire, England) molecular weight marker,
which was run in the first lane beside the samples. Negative control lanes
contained solution without the antibody. Boiled testicle, prostate and kidney
lysates incubated with the mouse anti-mouse and the rabbit anti-human
urokinase antibodies produced strong bands at approximately 50kDa and 33kDa.
Boiled concentrated urine and unconcentrated urine incubated with the mouse
anti-mouse, the mouse anti-human urokinase, and the rabbit anti-human
antibodies produced strong bands at approximately 50kDa and 33kDa (figures
6.8 and 6.9).
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Figure 6.8 Western Blot showing immunoprecipitated uPA protein bands at 50kDa and 30 kDa
molecular weights as compared to the perfect protein molecular weight marker using the mouse
anti-mouse uPA antibody (H77A10, Molecular Innovations) as the primary antibody. MWM,
Perfect Protein™ HRP Western Blot (69078-3, Novagen) molecular weight marker; Urine,
concentrated samples; Straight, unconcentrated sample; Ab, antibody used to immunoprecipitate
the sample; No Ab, Antibody was not added to the immunoprecipitation; kDa, molecular weight in
kilodaltons.

Figure 6.9 Western Blot showing immunoprecipitated uPA bands at 50 kDa and 35 kDa using the
rabbit anti-human uPA antibody. kDa, molecular weight in kilodaltons.

6.6.4 Urokinase Receptor with Immunoprecipitation
All samples were evaluated for molecular weight by comparing the
generated proteins bands with Rainbow Markers (RPN800, Amersham
Biosciences, Buckinghamshire, England) molecular weight marker which was run
in the first lane beside the samples. Immunoprecipitated boiled kidney, testicle
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and prostate lysates incubated with mouse anti-human urokinase receptor
antibody produced strong bands at approximately 60kDa (figure 6.10).

Figure 6.10 Western Blot showing immunoprecipitated uPAR bands at 60 kDa, as compared to
Rainbow Marker, using the mouse anti-human uPAR antibody. kDa, molecular weight in
kilodaltons.

6.7 Discussion
We have identified proteins in the tissues and urine of healthy dogs, with
antibodies directed against human and mouse uPA and human uPAR. The uPA
antibodies detected a protein in the urine, kidney, prostate and testicle from
healthy dogs which is the same molecular weight as uPA in both the high
molecular weight form (53 kDa) and the low molecular weight form (33 kDa). A
high molecular weight band for uPA is expected at approximately 50 kDa and the
low molecular weight band is generally at approximately 30 kDa.10, 11 In the
western blots run with pure uPA as a control, the proteins bands were present at
the same molecular weight as the pure uPA which further supports that the
bands we identified are high and low molecular weight uPA. The uPAR antibody
detected a protein in immunoprecipitated kidney, testicle and prostate from
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healthy dogs which is the same molecular weight as uPAR. The band at 55 kDa
is within the reported reference range for uPA at 55-60 kDa.12, 13
This would provide evidence that urokinase and urokinase receptor-like
proteins are present in the urinary tract and urine of healthy dogs. This also
suggests that antibodies against mouse and human uPA and human uPAR can
be used to detect these proteins in the dog. The results from our Western Blot
analysis with the mouse anti-mouse uPA antibody were also duplicated at the
Molecular Innovations laboratory in Southfield Michigan.
Immunoprecipitation was used to concentrate uPA from urine, testicle,
prostate and kidney. Immunoprecipitation was also used to concentrate uPAR in
kidney, testicle and prostate samples. The uPA-like concentration in the urine of
healthy dogs appears to be low. Western blot without immunoprecipitation
resulted in very faint or no bands. Immunoprecipitation enhanced visualization of
bands for uPA in concentrated and unconcentrated urine. These findings suggest
that uPA is present in urine but in small quantities.
Immunoprecipitation was not as necessary in the tissue samples. Kidney
samples produced consistently strong bands in the western blot analysis.
Prostate and testicle produced bands, but they were often much weaker and the
immunoprecipitation enhanced the visualization of the bands.
We did not measure the weight of the kidney, prostate and testicle tissues
prior to desiccation therefore we cannot compare the intensities of the bands in a
single Western blot to quantify the amount of uPA and uPAR within the samples.
Western blots are at best semiquantitative and a better method of comparing
protein concentrations would be in an ELISA or activity assay such as the
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fluorescence assay discussed in Chapter 5, Fluorogenic and ELISA Assays for
Urokinase in Urine.
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Chapter 7 Localization of Urokinase and Urokinase Receptor
Using Immunohistochemistry
7.1 Immunohistochemistry Introduction
Immunohistochemistry is the localization of antigens in tissue sections
through antigen-antibody interactions that are visualized microscopically via a
marker such as fluorescent dye, enzyme, radioactive element or colloidal gold.1, 2
Immunohistochemistry identifies the distribution of specific cellular components
within a cell or tissue. The term immunohistochemistry is used interchangeably
with immunocytochemistry and immunostaining.
Immunohistochemistry is an ELISA reaction, in which a primary antibody
is applied to the tissue with a secondary, labeled-antibody then applied to detect
the bound primary antibody.1, 2 A typical immunohistochemical protocol involves:
1.

Fixation of the tissue - Fresh frozen tissue can be used and for
some antigens, is required. Although frozen tissues have the best
antigen preservation they are more difficult to work with and
preservation of tissue architecture is poor.2, 3 Tissues preserved in a
fixative of commonly formalin is preferred and provides better
preservation of tissue architecture with “minimal” loss of tissue
antigenicity. 1, 3 Fixed tissues are then embedded in paraffin for
sectioning. Paraffin embedding may cause some shrinkage or
distortion, but will preserve the tissue architecture.3 Other fixation
solutions include mercuric chloride-based fixatives, which cause
minimum distortion but have poor tissue penetration, and acetone,
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which has excellent antigen preservation but very poor tissue
preservation. Acetone is preferred for cell smears.3
2.

Antigen retrieval - Fixation and embedding can cause antigen
masking.2, 4 Some epitopes are formalin sensitive and undergo
substantial change.4 Other epitopes are formalin-resistant and
remain unchanged. Cross-linking of unrelated proteins to the target
antigen is also possible. Both enzymatic and heat-mediated antigen
retrieval are used to overcome antigen loss. 2, 4 Enzymatic retrieval
can be used alone or in combination with heat-induced antigen
retrieval. Enzymatic or proteolytic retrieval works by etching the
tissue and allowing hidden determinants to be exposed. Enzymes
used include chymotrypsin and pepsin. Digestion procedures are
often combined with heating by microwave or pressure-cooking to
enhance retrieval of antigens. The energy from the heating is
believed to break some of the bonds formed during fixation.
Tissues to be heat treated may be immersed in retrieval solutions
such as citrate prior to processing.

3.

Endogenous enzyme block – All hemoproteins contain endogenous
peroxidase activity which results in increased background staining
on immunohistochemistry slides. Peroxidase activity can be
suppressed by incubating formalin fixed tissues in 3% H2O2 prior to
beginning staining. This is especially important in red blood cells,
leukocytes, muscle, liver and kidney.5

96

4.

Avidin-biotin block – Biotin is present in many tissues including the
liver, mammary gland, adipose tissue and kidney and can result in
false positive staining, falsely indicating the presence of an antigen.
Avidin or streptavidin are commonly used as blocking agents which
suppress endogenous biotin by binding the biotin with the avidin or
streptavidin making the biotin unavailable for binding with
antibodies used in the immunohistochemical stain. 5

5.

Blocking nonspecific sites – Blocking reactive sites in tissues is
important for an immunohistochemical reaction. Non-immune
serum from the host species of the secondary antibody is applied to
the tissue at the beginning of the procedure. The serum adheres to
the protein-binding sites by nonspecific adsorption or by binding of
specific, but unwanted, serum antibodies to antigens in the tissue.1

6.

Incubation with primary antibody – The primary antibody may be
directly labeled with a detection enzyme (horseradish peroxidase)
or fluorophore (Fluorescein) or unlabeled, allowing detection with a
labeled secondary antibody. Choice of primary antibody depends
on the antigen of interest. Homology between species within an
antigen allows use of antibodies from other species. Choice of a
monoclonal or polyclonal antibody is also important and again
depends on the species of interest and the target antigen. Dilutions
for each antibody and tissue must be optimized for the system
being used. The optimal dilution gives the strongest specific antigen
staining with the lowest non-specific background.1, 2
97

7.

Incubation with a secondary antibody-enzyme conjugate – If a
system using a secondary antibody is selected, the secondary
antibody is labeled with either an enzymatic or fluorescent label.
The secondary antibody is generated against the immunoglobulins
of the primary antibody source. For example, if the primary antibody
is raised in a mouse, the secondary antibody could be goat antimouse. Dilutions for the secondary antibody must also be optimized
for the system being used.1, 2 Methods to amplify the signal include
biotinylated compounds such as in the ABC procedure and chain
polymer-conjugated technology such as with the biotin free
EnVision™ system.2, 6

8.

Enzyme-mediated detection – Enzymatic color change or
fluorescence is required to visualize the final ELISA reaction in the
tissue. Horseradish peroxidase is commonly used and will react
with a chromogenic substrate to cause a color change. The color
change depends on the chromogen chosen.7

9.

Controls – Negative tissue controls must be processed identically to
the tissue being investigated and should not contain the relevant
tissue marker. Positive tissue controls must be processed
identically to the tissue being investigated and must contain the
target protein. Internal tissue controls contain the target antigen of
the tissues being investigated and also in adjacent normal tissue as
is the case with many tumor samples which contain normal and
affected tissue.8
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Stained tissues can be described based on subjective evaluation of the
staining intensity within the tissue and specific cell types. Stained tissue can also
be assessed semi-quantitatively using software that codes specific intensities.
7.2 Immunohistochemistry for Urokinase and Urokinase Receptor
Detection

7.2.1 Samples
Tissue samples were harvested and processed as described in Chapter 4,
Sample Selection and Preparation. Slides cut from the same tissue block were
used for both the urokinase and urokinase receptor immunohistochemistry.
7.2.2 Antibodies
•

Mouse Monoclonal to mouse uPA – A capture monoclonal antibody
produced in a uPA knockout mouse. IgG fraction purified by Protein A
Sepharose. (H77A10, Molecular Innovations, Southfield, MI)

•

Monoclonal antibody against human urokinase B-chain – A murine IgG1
monoclonal antibody directed against a B-chain epitope of human
urokinase, near the catalytic site. Reacts with free and receptor bound,
single and two chain (HMW) urokinase and the B-chain (33kDa) fragment.
(3689, American Diagnostica Inc., Stanford, CT)

•

Monoclonal antibody against human uPA receptor (CD 87) – A murine
monoclonal antibody, subclass IgG2a, recognizing the human urokinase
receptor. It binds with both unoccupied and occupied uPAR, to soluble
uPAR and to uPAR inside both normal blood cells and tumor cells. (3936,
American Diagnostica Inc., Stanford, CT)
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7.2.3 Immunohistochemistry Technique for Urokinase Detection

Figure 7.1 Schematic of the two step EnVision System for uPA detection in canine tissue
sections. The dextran chain allows for multiple sites of secondary antibody and enzyme
attachment to the primary antibody. This results in signal amplification.

All immunohistochemical studies were performed on paraffin embedded
sections (4µm). For urokinase detection, endogenous enzyme block was
performed using 0.3% hydrogen peroxide for 10 minutes. Sections were then
treated with Proteinase K for 2 minutes for enzyme retrieval followed by protein
block with horse serum for 30 minutes. The sections were incubated for 30
minutes with Primary mouse anti-mouse uPA antibody at 1:200 dilutions. The
primary antibody was omitted for negative controls. The secondary antibody
system used the mouse EnVision™ system, which uses a biotin free chain
polymer-conjugated technology with horseradish peroxidase as the enzyme. This
incubation was performed for 30 minutes. The sections were then incubated for 8
minutes with the chromogen NovaRed to allow visualization of the antigen100

antibody complexes (figure 7.1). Slides were counterstained with hematoxylin for
5 minutes. Intensity of staining was subjectively evaluated by one investigator.
Cell types staining were identified and described.
7.2.4 Immunohistochemistry Technique for Urokinase Receptor
Detection
For urokinase receptor detection endogenous, enzyme block was
performed using 0.3% hydrogen peroxide for 10 minutes. Sections were then
treated with high pH TRS for 2 minutes for enzyme retrieval followed by protein
block with horse serum for 30 minutes. The sections were incubated for 60
minutes the with primary antibody mouse anti-human uPAR at a 1:100 dilution.
The secondary antibody system used the mouse EnVision™ system, which uses
a biotin free chain polymer-conjugated technology with horseradish peroxidase
as the enzyme. The sections were then incubated for 8 minutes with the
chromogen NovaRed to allow visualization of the antigen-antibody complexes.
Slides were counterstained with hematoxylin for 5 minutes. Intensity of staining
was subjectively evaluated by one investigator. Cell types staining were identified
and described.
7.3 Problems
The antibody chosen for our tissue samples was the mouse anti-mouse
monoclonal antibody from Innovative Research which is produced using
urokinase knock-out mice. Our immunohistochemistry protocol was based on the
protocol from Innovative Research. One problem was over digestion of the
tissues by the enzymatic antigen retrieval system. This was especially
problematic with the testicular and prostate tissue. Use of a 1:2 dilution protocol
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for the Proteinase K solved this problem. Increased background was also an
issue due to known endogenous biotin in the kidney. This was overcome by
using an EnVision system which uses a biotin free chain polymer-conjugated
technology as the secondary antibody system.
Another problem encountered was with orientation of the tissue samples
for mounting. In some of the urinary bladder, urethra and ureter samples the
tissues required reorientation with the paraffin blocks to allow cross sections
which contained mucosa. This could have been prevented by more careful
examination of each tissue sample at the time of embedding. Smudging of some
of the mucosal borders was also evident. This can be prevented by fixing the
samples prior to cutting for paraffin embedding. Freezing of the samples may
have contributed to loss of some of the mucosal edges as well making the
mucosal lining more susceptible to damage when being placed in the cassettes
for paraffin embedding. Urokinase and urokinase receptor epitopes in canine
tissue do not appear to be masked direct fixation in formalin, so this technique is
acceptable. Formalin fixation provides good preservation of architecture.
7.4 Results
All organs in the urinary tract showed evidence of staining for urokinase
and most tissues were positive for urokinase receptor. Other supporting tissues
such as smooth muscle, skeletal muscle, vascular endothelial cells and
leukocytes also showed evidence of staining for urokinase and urokinase
receptor (appendix tables 4, 5, 6, 7, 8 and 9).
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7.4.1 Urokinase and Kidney

Figure 7.2 Immunohistochemical staining of uPA within kidney. (100X magnification) Staining is
noted in the cytoplasm of the epithelial cells lining the renal tubules. Some plasma staining is
noted within the glomeruli.

Staining in the kidney was consistent was consistent for male and female dogs
and for castrated and intact male dogs (appendix table 4) Staining was red to
red-brown and uniform in the cytoplasm of the cells. There was intense staining
in tubular epithelial cells throughout the cortex and medulla of the kidney. In
some samples cells in the medullary tubules stained slightly more intensely than
cells in the proximal convoluted tubules. Staining was evident in the endothelial
cells of the glomeruli in some kidneys. Inflammatory cells and endothelial cells of
both arteries and veins also stained (figure 7.2). Staining was evident in the
mucosa of the renal pelvis within the cytoplasm of the luminal cells in the
transitional epithelium. Staining of the transitional epithelium was segmental. The
renal pelvis that was involuted stained uniformly throughout the cytoplasm of the
entire layer of cells. The renal pelvis which protruded into the pelvis stained along
the surface or not at all (figure 7.3).
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Figure 7.3 Immunohistochemical staining of uPA within the transitional epithelium of the renal
pelvis. (100X magnification) Staining of cytoplasm of the transitional epithelial cells is present.
Staining is more intense in the luminal cells and is segmental. Staining of the cytoplasm of
endothelial cells of veins and inflammatory cells within the renal parenchyma is visible.

7.4.2 Urokinase Receptor and Kidney
Staining in the kidney was consistent was consistent for male and female
dogs and for castrated and intact male dogs (appendix table 4). Staining was red
to red-brown and appeared more granular than the urokinase staining. Intense
granular staining was noted in cytoplasm of inflammatory cells in the parenchyma
and in the blood vessels. Granular staining was present along the basement
membranes of the epithelial cells in both proximal and medullary tubules (figure
7.4). The mucosa in the renal pelvis showed granular staining along the surface
and within cytoplasm of the luminal cells of the transitional epithelium.
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Figure 7.4 Immunohistochemical staining of uPAR in the kidney. (0000 magnification) Granular
staining along the basement membrane of tubular epithelial cells. Slight cytoplasmic staining of
these tubular cells is also evident.

7.4.3 Urokinase and Ureter
There was intense and uniform staining of the transitional epithelium of the
ureter in all dogs evaluated (appendix table 5). Staining was along the luminal
cell membrane of the surface epithelial cells and within the cytoplasm throughout
all layers of transitional epithelial cells of the mucosal lining. The cytoplasm of
inflammatory cells within the connective tissue of the ureter wall and vascular
endothelial cells were stained (figure 7.5).
7.4.4 Urokinase Receptor and Ureter
There was granular staining was noted along the membrane of the luminal
cells at the surface of the transitional epithelium lining the ureter in all dogs
evaluated (appendix table 5). Granular cytoplasmic staining was noted in the first
and sometimes second layer of cells. Inflammatory cells stained positive. No
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Figure 7.5 Immunohistochemical staining of uPA in the ureter. Membrane staining is noted along
the luminal surface of the cells in the transitional epithelium. The cytoplasm of all cells in the
transitional epithelium is staining. Also staining are the inflammatory cells in the connective tissue
of the ureter wall and vascular endothelial cells.

Figure 7.6 Immunohistochemical staining of uPAR in the ureter. Granular membrane staining is
noted along the luminal surface of the cells in the transitional epithelium. The cytoplasm of cells in
the first two cells layer in the epithelium is staining. Also staining are the inflammatory cells in the
connective tissue of the ureter wall
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staining was noted in the deeper cells of the transitional epithelium. Inflammatory
cells within the connective tissue of the ureter wall were stained (figure 7.6).
7.4.5 Urokinase and Urinary Bladder
There was staining of the transitional epithelium on the urinary bladder in
all dogs evaluated (appendix table 6). Staining was variable with some sections
of the mucosa stained throughout all cell layers on the luminal membrane surface
and within the cytoplasm. Other sections only showed staining on the surface
layer or not at all. The sections which had staining appear invaginated and there
was increased vacuolization of the cytoplasm. Other cells which stained positive
were the smooth muscle cells and skeletal muscle cells, endothelial cells of
vessels and inflammatory cells within the bladder wall. These cells all stained in
the cytoplasm. Two of the urinary bladder sections showed inflammation
consistent with chronic cystitis. These samples displayed intense urokinase
staining along the mucosa in the same regions as the normal bladder (figure 7.7)
7.4.6 Urokinase Receptor and Urinary Bladder
Granular staining was noted along the luminal surface membrane of the
cells in the transitional epithelium in all dogs evaluated (appendix table 6).
Granular cytoplasmic staining of the cells in the transitional epithelium was
evident in some regions extending only to the first one to two layers of cells.
Inflammatory cells within the wall stained consistently (figure 7.8).
7.4.7 Urokinase and Prostate
Staining in the prostate was highly variable (appendix table 8). Male 1
through 5 were intact, males 6 and 7 were castrated. Male 1 had a mature
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.
Figure 7.7 Immunohistochemical staining of uPA in the urinary bladder. Staining is noted in the
cytoplasm of cells in the transitional epithelium in the invaginated section. These cells are also
more vacuolated than the cells in the remaining regions. Staining is also noted along the surface
membrane of the cells of the remaining mucosa.

Figure 7.8 Immunohistochemical staining of uPAR within the urinary bladder. Intense granular
staining is noted along the membrane of the luminal cells of the transitional epithelium. Granular
cytoplasmic staining is noted within the first cell layer of the transitional epithelium and
inflammatory cells in the urinary bladder wall.
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prostate and showed variable light staining in the cytoplasm of the connective
tissue cells of glandular epithelium but most glandular tissue did not stain.
Epithelial cells lining the prostatic ducts did not stain. Inflammatory cells within
the connective tissue of the prostate stained positive. Male 2 had a mature
prostate with some evidence of hyperplasia. Some faint staining of the cytoplasm
of glandular cells was noted but the majority of the glandular cells did not stain.
The prostate of male 3 was mature and hyperplastic. Fixation of the tissue was
not optimal but showed very weak staining of some glandular cells. Male 4 was a
young dog and the prostate had very little acinar development. Urokinase
staining was prominent in the regions of developing ducts in the epithelial cells
lining the ducts. Staining was decreased but still present in comparable cells in
more differentiated ducts. Staining was also visualized in inflammatory cells
within the glandular connective tissue (figure 7.9). Male 5 was a mature dog
prostate sample with multiple hyperplastic and cystic regions. Epithelium within
the ducts and the glandular epithelium of the cystic regions showed moderate to
intense staining. Very weak to no staining was noted in the glandular cells of the
hyperplastic regions. Male 6 had normal prostate tissue and no staining was
noted in glands or ducts. Very light staining was noted in the cytoplasm of a few
foamy prostatic cells. The prostate of Male 7 was hypoplastic or atrophied.
Prostatic glandular epithelial tissue and apical cytoplasm of the epithelial cells
within the ducts stained. Inflammatory cells in the connective tissue and vascular
endothelium stained. Some staining was noted in the cytoplasm of epithelial cells
lining primitive or poorly differentiated ducts.
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Figure 7.9 Immunohistochemical staining of uPA in the prostate of Male 4. Epithelial cells along
surrounding the duct show staining at the apical membrane and within the cytoplasm.

7.4.8 Urokinase Receptor and Prostate
Most of the prostatic sections did not stain for urokinase receptor staining
(appendix table 8). Inflammatory cells in the connective tissue stained well in all
samples, acting as an internal control. Male 4 was intact and granular staining
was visualized in the epithelial cells of the developing ducts at both the apical
surface and the cytoplasm. Staining was also noted in the more mature ducts at
the apical borders of the epithelial cells at the same intensity as the less mature
ducts. Intense staining was evident in interstitial inflammatory cells (figure 7.10).
Male 7 was neutered and the prostate appeared hypoplastic or atrophied
suggesting castration had been performed at a young age or that the gland was
involuting. Granular staining was noted in the apical region of epithelial cells
lining primitive or poorly developed ducts. Inflammatory cells in the glandular
connective tissue stained.
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Figure 7.10 Immunohistochemical staining of uPAR in the prostate of Male 4. Intense staining is
noted along the cell membranes and within the cytoplasm of the epithelial cells lining the
developing acinar structures.

7.4.9 Urokinase and Testicle
Cytoplasm in the cells in the testicle stained intensely in all samples
throughout the interstitial cells and the seminiferous tubules, including all phases
of spermatogonia (figure 7.11 and appendix table 9).
7.4.10 Urokinase Receptor and Testicle
Testicular cells did not to stain well for urokinase receptor. Very faint
staining was noted in the cytoplasm of interstitial cells. The seminiferous tubules
and the contained spermatogonia did not stain. Inflammatory cells in the
connective tissue still stained (figure 7.12 and appendix table 9)
7.4.11 Urokinase and Urethra
Transitional epithelium within the ureter showed consistent staining along
the luminal border and within the cytoplasm of the cells extending all the way
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Figure 7.11 Immunohistochemical staining uPA in the testicle. Intense staining in noted
throughout the interstitial cells and the seminiferous tubules including all phases of
spermatogonia.

Figure 7.12 Immunohistochemical staining of uPAR in the testicle. Very faint staining of the
cytoplasm of the interstitial cells is seen.

through the mucosa in all dogs evaluated (appendix table 7). This staining was
similar to the urinary bladder mucosa in those areas which appeared to have
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increased numbers of cells with vacuolated cytoplasm and was invaginated. In
other areas of the mucosa, the staining was more luminal and in some places no
staining. Inflammatory cells in the connective tissue of the urethral wall stained
well (figure 7.14) There was no difference in the transitional epithelium of the
prostatic (figure 7.13) and penile urethra of male dogs.
7.4.12 Urokinase Receptor and Ureter
The transitional epithelium of the ureter stained for urokinase receptor on
the luminal surface of the cells and within the cytoplasm of the cells closest to the
lumen (appendix table 7). The staining was granular. Inflammatory cells in the
connective tissue of the urethral wall stained positive (figure 7.16) Cells of the
transitional epithelium of the prostatic urethra (figure 7.15) stained more intensely
than the cells of the transitional epithelium of the penile urethra in some sections.

Figure 7.13 Immunohistochemical staining of uPA in the prostatic urethra. Staining is noted in the
cytoplasm of cells in the transitional epithelium in the invaginated section. These cells are also
more vacuolated than the cells in the remaining regions. Staining is also noted along the surface
membrane of the cells of the remaining mucosa.
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Figure 7.14 Immunohistochemical staining of uPA in the urethra. Staining is noted along the
entire layer of luminal cells along the membrane and in the cytoplasm. Staining continues
throughout the cell layers in the mucosa in some regions of the section examined. Cytoplasm of
inflammatory cells and vascular endothelial cells stain positive.

Figure 7.15 Immunohistochemical staining of uPAR in the prostatic urethra.
Light staining is present along the outer membrane of the luminal transitional epithelium and
within the cytoplasm of some epithelial cells in the upper corner of the invagination. Inflammatory
cells in the urethral wall are staining intensely.
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Figure 7.16 Immunohistochemical staining of uPAR in the urethra. Intense granular staining is
noted along the membrane of the luminal cells of the transitional epithelium. Granular cytoplasmic
staining is noted within the cell layers of the transitional epithelium and inflammatory cells in the
urethral wall.

7.5 Discussion
Urokinase and urokinase receptor appear to be present in all tissues of
the urinary tract of the dog. Urokinase receptor appears to be present in most
tissues except the testicle.
The kidney specimens evaluated in our study showed staining for
urokinase in the epithelium of the renal tubules throughout the kidney and
staining along the epithelial cells of the glomeruli in most specimens. Urokinase
expression in the kidney is consistent with that reported in the literature for
people, mice and rats. Immunohistochemistry cannot differentiate whether the
antigen is present due to synthesis within the cells or because of binding to a
receptor in or on the cell membrane. However, invitro and tissue studies of cells
lines from human mesangial and tubule cells show that urokinase is synthesized
115

and secreted by glomerular visceral epithelial cells and kidney tubular epithelial
cells.9-11 Given these findings in other mammalian species the urokinase in the
renal tubules and glomeruli of the dog is likely synthesized there also. To verify
this, cell culture studies would be required to document secretion of urokinase
into the cell medium.
Within the kidney urokinase staining was also visualized along the
transitional epithelium of the renal pelvis. Staining was intense and throughout
the cytoplasm of all cell layers. Presence of and fibrinolytic activity of urokinase
has been documented in epithelial cells of the renal calyces.11, 12 Urokinase may
be produced the transitional epithelial cells. This has been shown to be the case
in bovine urothelium. 13 To my knowledge this has not been investigated in other
species. Presence of urokinase in the tubular structures of the urinary tract is
important to maintain patency of the urinary tract in face of hemorrhage and fibrin
deposition.
Urokinase receptor staining in the tissues of the kidney was limited to the
basement membranes of renal tubular cells. Urokinase receptor staining is not
noted in normal murine kidney samples. 14 This is consistent with findings from
people in which urokinase receptor was not noted in the tubules of the kidneys
from healthy people presenting as donors.15 In another study glomerular cells did
not stain in healthy kidney samples.16 In the dog kidney studied, uPAR was
present along the basement membrane. This could indicate that the canine
kidney does produce uPAR and is different than human kidneys in healthy
subjects. Many of the dogs in our study did have heartworm disease as evident
by the identification of microfilaria in glomeruli. This may have resulted in mild
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interstitial disease and upregulation of uPAR in these dogs. More samples would
have to be evaluated from known heartworm negative dogs to answer this
question. Based on this study we can only say that urokinase receptor is present
in the kidney of dogs. The role of uPAR and sites of production cannot be
determined without additional studies such as cell culture.
Transitional epithelium in the renal pelvis showed positive urokinase
receptor staining along the surface and within cytoplasm of luminal cells in the
same regions as urokinase staining in the renal pelvis. This may indicate that at
least some of the urokinase in this tissue is bound to urokinase receptor at the
cell surface or that urokinase is produced in this tissue.
The pattern of urokinase staining along the mucosal surfaces of the
urinary tract was consistent between section and site. The ureter stained most
intensely along the entire region of transitional epithelium available for
examination on the slide preparations. Within the urinary bladder and the ureter
the staining was more variable. These tissues stained but only in some regions.
The regions more likely to stain were areas which appeared to be invaginated
and the cytoplasm of the staining cells had increased vacuolization. Areas of the
mucosa which had decreased staining often stained along the luminal surface
edge and sometimes into the cytoplasm of the first layer of cells. The significance
of this finding is unknown. The stained regions may be areas of urokinase
binding to cells which are damaged or being renewed or these regions may be
indicative of urokinase producing cells with the transitional epithelium. Bovine
urothelium has been shown to produce urokinase in culture medium.13
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Urokinase receptor showed a similar pattern of staining to urokinase. It
differed in that its appearance was granular and the staining was limited to the
luminal surface and the cytoplasm of the first one to two layers of cells. It did not
extend to the inner most layers of the mucosa. This pattern could indicate that
the urokinase is being produced and secreted by the deeper cells layers and
then bound to the luminal layers. These layers are rapidly turned over in the
urinary tract.
The variability of urokinase expression within the prostate tissue is
interesting. I do not believe that this series of samples adequately describes the
presence of urokinase and urokinase receptor in this tissue type, as presence
seems to depend greatly on stage of development within the prostate gland. It
has been shown that urokinase production in rats is influenced by hormones.17-19
In these rats, immunohistochemical evaluation found urokinase to be present in
scattered cells at the surface of the epithelium facing the lumen of the glandular
ducts. This staining increased in epithelium after castration suggesting a role for
urokinase in the involution of the ventral prostate of the rat as well as in the
normal turnover of prostate epithelium.19 Increased activity of plasminogen
activators was noted with use of plasminogen activator assays in developing
prostate tissue which decreased when development was complete.17 This is
consistent with the role of urokinase and other plasminogen activators in tissue
remodeling. This is supported by the findings of this study in which expression of
urokinase and urokinase receptor appeared to be limited to only developing
ductile tissue. More samples at set developmental stages would be required to
adequately characterize the presence of urokinase within the prostate of the dog.
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Urokinase receptor did not stain the majority of prostate sample evaluated.
Male 4 was intact and staining was visualized in the epithelial cells of the
developing ducts at both the apical surface and the cytoplasm. Staining was also
noted in the more mature ducts at the apical borders of the epithelial cells at the
same intensity as the less mature ducts. Male 7 was neutered but the prostate
appeared hypoplastic or atrophied suggesting castration had been performed at
a young age and maybe recently leading to involution. Granular staining was
noted around primitive or poorly developed ducts in the apical region. Staining
urokinase and urokinase receptor in the same regions leads to question of
whether urokinase is produced in these tissues or bound to the cells. It is
possible, given the abundance of urokinase within the other tissues of the urinary
tract, that urokinase is truly bound at this site and not produced. Answering this
question would require cell culture and measurement of products in the culture
medium. Urokinase and urokinase receptor may contribute to tissue remodeling
in the prostate of the dog. The importance of uPA and uPAR in development of
the gland and involution after castration has been shown in rat models of
prostate development.18, 20, 21 Urokinase and urokinase receptor are known to be
important in tissue remodeling due to the ability of the uPA-uPAR complex to
degrade basement membranes in inflammation and neoplasia.22
Intense staining for uPA was seen in testicle sections. Seminiferous
tubules and interstial cells all stained in the dog. This has been documented in
the rhesus monkey and man.23, 24, 25 The role of urokinase in the testicle is
believed to be in spermatogenesis and sperm motility. It has been suggested that
infertility in some men may be due decreased levels of urokinase within the
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testicle.25 The role of urokinase in the dog cannot be determined by
immunohistochemistry. Urokinase receptor did not stain in the seminiferous
tubules of the dog. Staining was very weak in the cytoplasm of the interstitial
cells. Urokinase may be produced in the testicle is produced there and not
bound. In vitro studies in cell culture would provide further information on exactly
which cell types produce urokinase.
The expectation that urokinase would be present in the canine urinary
tract is extrapolated from evidence of its presence in people. Actual identification
of urokinase in the canine urinary tract has not been previously performed. Cell
types which stained positive for urokinase and urokinase receptor in the tissues
from the dog are consistent with those described in both people, rats, monkeys
and mice. This lends support to the results of the immunohistochemical staining.
Currently there are no specific antibodies for canine urokinase. Use of an
antibody from another species to identify uPA and uPAR poses problems when
interpreting results. Use of antibodies which were successfully used in our
immunoprecipitation and SDS PAGE/ Western Blot also helps to validate the use
of these antibodies in the canine tissues and support the conclusions that uPA an
uPAR are present in the urinary tract of the healthy dog.
Selection of an antibody for identification of urokinase in the canine urinary
tract required consideration of any documentation of cross species reactivity of
that antibody. Different antigens have greater or less degree of species
specificity than others. At least two investigations have used a mouse anti-human
monoclonal antibody from American Diagnostica to successfully detect urokinase
within bovine urothelium and rat mammary tissue.13, 26 A third investigation used
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a polyclonal goat antihuman uPA antibody to demonstrate uPA in bovine
endothelial cells.27 This cross species reactivity would suggest that at least some
segment of the uPA protein structure is retained across some species and or
results suggest this includes the dog.
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Chapter 8 Conclusions
Identification of proteins such as urokinase and urokinase receptor in a
species without species specific antibodies provides numerous challenges. In
veterinary medicine we must often rely on antibodies produced for human
medical research and therefore our findings cannot always be conclusive and we
are left stating that, as in this case, we have identified urokinase-like and
urokinase receptor-like proteins and activity in the samples tested.
Uses of multiple methods of detection which support the finding of each
test help validate the use of uPA and uPAR antibodies directed against mouse
and human proteins for detection of the homologous protein in dogs. SDSPAGE/Western Blot and immunoprecipitation all demonstrated antibody binding
with uPA-like and uPAR-like protein at the accepted molecular weight for these
proteins. Immunohistochemistry showed positive staining in tissues of the urinary
tract from the dog in cells consistent with descriptions from other mammals
including people, rats, mice and monkeys. The ELISA assay also detected
presence of a uPA-like protein in concentrated urine samples. All of these
immunological techniques were run with the same mouse anti-mouse
monoclonal antibody from Innovative Research.
The fluorescence assay and ELISA assay are promising methods to
evaluate concentration of uPA in urine samples. They require more time and
work to eliminate variability and improve the results. Whether or not they will
provide information that may be useful in a clinical setting is not determined since
recent literature has conflicted as to whether renal disease would result in
increased or decreased release of uPA into the urine. These assays may be very
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useful, however, in evaluating tissues in studies on wound healing and cancer
growth and metastasis.
This research has resulted in very strong evidence that urokinase and
urokinase receptor are present in the urinary tract of the healthy dog. The
physiologic, pathophysiologic and clinical roles of these proteins are yet to be
determined.
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APPENDIX: RAW DATA
Table 1 Clinical Parameters for establishing health of dogs for urine collection
Group
f
f
f
f
f
f
f
f
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc

N
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
9
10
11
12
13
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
2
3
4
5
6
7
8
9
10

Case
80735
79737
80810
74708
81588
81020
81038
81833
62001
81144
81357
76045
81337
81375
81414
81441
81188
81496
76846
81517
81528
81252
67922
80982
81451
81460
81419
81440
81482
54704
81610
81618
81748
81892
81913
81108
81962
78717
72533
81360
81380
81356
78701
81445
78785
81494
81511

BUN
12
9
20
15
25
8
20
15
9
13
17
18
16
9
17
16
22
14
11
9
10
20
14
16
11
10
17
25
6
17
18
15
10
8
10
13
17
21
16
7
22
20
14
36
9
21

Creatinine

Phosphorus

1.2
0.7

4.5
4.5

Urine Spec Grav
1.019
1.037
1.049
1.015

0.8
0.7
0.6
0.8
1
0.9
1.3
0.9
0.7
0.9
0.9
0.7
1
0.8
0.3

3.2
4.9
2.6
4.5
4.1
3.9
3.6
3.5
3.1
7.9
5.1
5.1
2.8
2.7
5

1.1

3.7

1.1
1
0.6

4.7
3.8
3.4

0.9
0.3
0.4
0.9
1
0.7
1.2

4.2
7.7
4.1
4.3
4.7
4.2
4.8

0.4
1
1
0.7
0.4
1
1.2
1
0.8
0.9
1.3

5.7
4.1
4.5
3.1
4
4.3
4.3
2.6
5.3
4.5
6.6
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1.038
1.027
1.032
1.02
1.044
1.013
1.017
1.027
1.05
1.048
1.008
1.011
1.037
1.038
1.049
10.32
1.038
1.055
1.024
1.057
1.045
1.017
1.037
1.048
1.041
1.01
1.028
1.025
1.012
1.035

1.038
1.028
1.012

PCV
44.3
47
33
50
45
43.8
50
40
45.8
36.5
49
45
44.7
44.6
41.3
36.4
37.6
49.6
48.3
34.6
41.6
43.6
45
41
42
45
44
57
40
29
43
31
51
55
49
43
33
46
41
44
39
41
42
48
52
46
35

mc
mc
mc

11
12
13

48505
81635
81688

15
7
11

0.5
0.5
0.9

2.7
2.8
3.8

1.041
1.029
1.043

45
38
45

Key:
Groups
f = female intact
fs = female spayed
m = male intact
mc = male castrated
N = Dog number
Case – Louisiana State University veterinary Teaching Hospital and Clinic patient
number
BUN – blood urea nitrogen mg/dl
Creatinine – mg/dl
Phosphorus – mg/dl
Urine SG – Urine specific gravity
PCV – Packed cell volume %
Total protein – g/dl
Table 2 Fluorescence activity assay data
Sample

Pt #

M#1
M#2
M#3
M#4
M#5
M#6
M#7
M#8
M#9
M#10
M#11
M#12
M#13
M#14
M#15
M#16
F#1
F#2
F#3
F#4
F#6
F#7
F#8
F#9
M/N#1
M/N#2

81252
67922
80982
81451
81460
81419
81440
81482
54704
81610
81618
81748
81892
81913
81108
81962
80735
79737
80810
74708
81588
81020
81038
81833
78717
72533

Creat
57
234
103
356
410
65
87
89
213
150
435
466
109
261
514
127
123
159
176
380
223
95
415
393
86
128

Start
Vol
ml
50
12.9
45
19
13.5
16.2
2
48
6.5
4.5
13.5
47
45
42
5.5
11
52
11
17
48
10.5
30
49
50
56
19

End
Vol
ul
450
400
410
150
225
525
150
350
200
150
175
300
300
275
225
160
450
150
150
755
175
275
475
450
725
140

conc
factor
111.1111
32.25
109.7561
126.6667
60
30.85714
13.33333
137.1429
32.5
30
77.14286
156.6667
150
152.7273
24.44444
68.75
115.5556
73.33333
113.3333
63.57616
60
109.0909
103.1579
111.1111
77.24138
135.7143
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Fluoro
1

Fluoro
2

Fluoro
3

28
18
0
13
0
0
14
0
22
0
0
1
0
25
0
0
0
0
5
0
16
0
0
0
0
1

12
0
0
10
0
0
12
0
25
0
0
0
0
35
0
0
0
40
0
12
5
0
0
0
2
0

30
11
39
0
0
0
3
0
43
0
0
0
0
49
0
0
0
43
0
15
5
0
0
0
0
0

uPA Conc
Fluoro
0.182055
0.075423
0.101431
0.059818
0
0
0.075432
0
0.234071
0
0
0.002601
0
0.283485
0
0
0
0.215865
0.013004
0.070221
0.06762
0
0
0
0.005202
0.002601

M/N#3
M/N#4
M/N#5
M/N#6
M/N#7
M/N#8
M/N#9
M/N#10
M/N#11
M/N#12
M/N#13
F/S#1
F/S#3
F/S#4
F/S#5
F/S#6
F/S#7
F/S#8
F/S#9
F/S#10
F/S#11
F/S#12
F/S#13
F/S#14

81360
81380
81356
78701
81445
78785
81494
81511
48505
81635
81688
62001
81144
81357
76045
81337
81375
81414
81441
81188
81496
76846
81517
81528

166
44
213
553
621
52
213
98
134
27
49
192
218
152
228
114
179
283
173
138
90
468
427
28

41
22
42
20
50.5
24
32.5
7.5
36
29
50
13.5
50
21.5
4.5
44
3.5
6.5
45
10.5
14
15.5
32.7
44

250
150
450
160
300
160
175
150
450
275
550
175
350
275
150
300
125
350
450
200
150
175
675
400

164
146.6667
93.33333
125
168.3333
150
185.7143
50
80
105.4545
90.90909
77.14286
142.8571
78.18182
30
146.6667
28
18.57143
100
52.5
93.33333
88.57143
48.44444
110

41
37
20
0
122
0
8
0
36
6
0
0
0
0
0
0
0
0
58
19
0
5
19
6

31
33
17
0
142
0
12
0
22
1
0
0
0
0
0
5
0
0
74
25
0
6
47
7

16
10
2
0
135
0
6
0
34
0
2
0
0
0
0
6
0
0
93
34
0
11
39
3

0.228869
0.208063
0.101431
0
1.035112
0
0.06762
0
0.239272
0.018205
0.005202
0
0
0
0
0.028609
0
0
0.585176
0.202861
0
0.057217
0.273082
0.041613

Key:
Groups
f = female intact
fs = female spayed
m = male intact
mc = male castrated
Sample = Dog number
Pt # – Louisiana State University Veterinary Teaching Hospital and Clinic patient
number
Creat – Urine creatinine mg/dl
Fluoro 1, 2 and 3 – Values of Fluorescence readings for each sample corrected
for background
uPA concentration fluoro – Concentrations of uPA in each samples as compared
to standard dilutions of uPA and a global fit standard curve extrapolated from the
standard curves run with each plate. Values are in ng/ml
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Figure 1 Sample Standard Curve for Fluorescence Data
Table 3 ELISA assay data
Grp
f
f
f
f
f
f
f
f
f
f
f
f
f
f
f
f
fs
fs
fs
fs
fs
fs
fs
fs
fs

N
1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
1
1
2
2
3
3
4
4
5

Case
80735
80735
79737
79737
80810
80810
74708
74708
81588
81588
81020
81020
81038
81038
81833
81833
62001
62001
81144
81144
81357
81357
76045
76045
81337

Sample
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1

Cr
mg/dl
123
123
159
159
176
176
380
380
223
223
95
95
415
415
393
393
192
192
218
218
152
152
228
228
114

Start
Vol ml
52
52
11
11
17
17
48
48
10.5
10.5
30
30
49
49
50
50
13.5
13.5
50
50
21.5
21.5
4.5
4.5
44

End
Vol ul
450
450
150
150
150
150
755
755
175
175
275
275
475
475
450
450
175
175
350
350
275
275
150
150
300
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uPA
ng/ml
32.693
.
.
.
22.634
.
19.4
15.089
8.622
-3.233
35.926
.
74.009
85.146
65.745
68.62
35.926
.
34.849
37.723
8.982
12.215
26.226
.
.

volcorr
0.28292019
.
.
.
0.19971176
.
0.30514583
0.2373374
0.1437
-0.0538833
0.32932167
.
0.71743418
0.8253949
0.591705
0.61758
0.46570741
.
0.243943
0.264061
0.11488605
0.15623837
0.8742
.
.

ng/mg
Cr/ml
0.02300164
.
.
.
0.01134726
.
0.00803015
0.00624572
0.00644395
-0.0024163
0.03466544
.
0.01728757
0.01988903
0.01505611
0.0157145
0.02425559
.
0.01119005
0.01211289
0.00755829
0.01027884
0.03834211
.
.

ng/mg Cr/ul
23.0016417
.
.
.
11.3472594
.
8.03015351
6.24572094
6.44394619
-2.416293
34.6654386
.
17.2875707
19.8890337
15.0561069
15.7145038
24.2555941
.
11.1900459
12.1128899
7.55829253
10.2788403
38.3421053
.
.

fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
fs
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
mc
mc

5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
1
1

81337
81375
81375
81414
81414
81441
81441
81188
81188
81496
81496
76846
76846
81517
81517
81528
81528
81252
81252
67922
67922
80982
80982
81451
81451
81460
81460
81419
81419
81440
81440
81482
81482
54704
54704
81610
81610
81618
81618
81748
81748
81892
81892
81913
81913
81108
81108
81962
81962
78717
78717

2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

114
179
179
283
283
173
173
138
138
90
90
468
468
427
427
28
28
57
57
234
234
103
103
356
356
410
410
65
65
87
87
89
89
213
213
150
150
435
435
466
466
109
109
261
261
514
514
127
127
86
86

44
3.5
3.5
6.5
6.5
45
45
10.5
10.5
14
14
15.5
15.5
32.7
32.7
44
44
50
50
12.9
12.9
45
45
19
19
13.5
13.5
16.2
16.2
2
2
48
48
6.5
6.5
4.5
4.5
13.5
13.5
47
47
45
45
42
42
5.5
5.5
11
11
56
56
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300
125
125
350
350
450
450
200
200
150
150
175
175
675
675
400
400
450
450
400
400
410
410
150
150
225
225
525
525
150
150
350
350
200
200
150
150
175
175
300
300
300
300
275
275
225
225
160
160
725
725

.
51.375
.
27.304
34.13
39.519
.
24.789
48.86
.
.
.
.
139.754
142.628
69.697
65.027
10.419
20.837
67.542
70.416
20.119
26.226
18.682
.
20.837
26.586
18.682
77.601
26.226
.
.
.
.
.
16.526
.
68.979
.
26.945
29.46
12.215
43.471
.
.
61.705
51.375
.
.
14.011
8.622

.
1.83482143
.
1.47021538
1.83776923
0.39519
.
0.47217143
0.93066667
.
.
.
.
2.88483028
2.94415596
0.63360909
0.59115455
0.093771
0.187533
2.09432558
2.18344186
0.18330644
0.238948
0.14748947
.
0.34728333
0.4431
0.60543519
2.51484722
1.96695
.
.
.
.
.
0.55086667
.
0.89417222
.
0.17198936
0.18804255
0.08143333
0.28980667
.
.
2.52429545
2.10170455
.
.
0.18139241
0.11162411

.
0.10250399
.
0.05195107
0.06493884
0.02284335
.
0.03421532
0.06743961
.
.
.
.
0.06756043
0.06894979
0.22628896
0.21112662
0.01645105
0.03290053
0.08950109
0.09330948
0.01779674
0.02319883
0.00414296
.
0.00847033
0.01080732
0.09314387
0.38689957
0.22608621
.
.
.
.
.
0.03672444
.
0.02055568
.
0.00369076
0.00403525
0.00747095
0.02658777
.
.
0.04911081
0.04088919
.
.
0.02109214
0.01297955

.
102.50399
.
51.9510737
64.9388421
22.8433526
.
34.2153209
67.4396135
.
.
.
.
67.560428
68.9497884
226.288961
211.126623
16.4510526
32.9005263
89.5010932
93.3094812
17.7967422
23.198835
4.14296274
.
8.4703252
10.8073171
93.1438746
386.899573
226.086207
.
.
.
.
.
36.7244444
.
20.5556833
.
3.69075883
4.03524792
7.47094801
26.5877676
.
.
49.1108065
40.8891935
.
.
21.0921408
12.9795473

mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc
mc

2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13

72533
72533
81360
81360
81380
81380
81356
81356
78701
78701
81445
81445
78785
78785
81494
81494
81511
81511
48505
48505
81635
81635
81688
81688

1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2

128
128
166
166
44
44
213
213
553
553
621
621
52
52
213
213
98
98
134
134
27
27
49
49

19
19
41
41
22
22
42
42
20
20
50.5
50.5
24
24
32.5
32.5
7.5
7.5
36
36
29
29
50
50

140
140
250
250
150
150
450
450
160
160
300
300
160
160
175
175
150
150
450
450
275
275
550
550

1.437
-2.874
59.279
66.464
.
.
.
.
93.409
.
66.823
86.583
.
.
.
.
36.645
.
54.608
63.949
10.419
10.778
38.441
28.741

0.01058842
-0.0211768
0.36145732
0.40526829
.
.
.
.
0.747272
.
0.39696832
0.51435446
.
.
.
.
0.7329
.
0.6826
0.7993625
0.09880086
0.10220517
0.422851
0.316151

0.00082722
-0.0016544
0.02177454
0.02441375
.
.
.
.
0.01351306
.
0.0063924
0.00828268
.
.
.
.
0.07478571
.
0.0509403
0.05965392
0.03659291
0.03785377
0.08629612
0.06452061

Key:
Groups
f = female intact
fs = female spayed
m = male intact
mc = male castrated
N = Dog number
Case – Louisiana State University veterinary Teaching Hospital and Clinic patient
number
Sample – denotes duplicate wells for samples, 1 or 2
Cr mg/dl – Creatinine value for each urine sample
Start Vol ml – Initial volume in milliliters of urine collected prior to filtration
End Vol ul – Final volume of urine in microliters after filtration.
uPA ng/ml – Concentration of uPA in each well in ng/ml
volcorr – concentration factor for each urine sample based on
start volume µl / end volume µl
ng/mg Cr/ml – (concentration of uPA in each sample / creatinine mg/dl)
corrected volume of urine
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0.82722039
-1.6544408
21.7745372
24.4137526
.
.
.
.
13.5130561
.
6.39240446
8.28268044
.
.
.
.
74.7857143
.
50.9402985
59.6539179
36.5929119
37.8537676
86.2961224
64.5206122

std curve #1
3.000

Absorbance

2.500
2.000
std curve #1

1.500
1.000
0.500
0.000
0

10

31

63

125

250

500

1000

Concentration (ng/m l)

Figure 2 Standard Curve for ELISA assay
Table 4 Immunohistochemistry results for uPA and uPAR in Kidney Sections
Sample
Male #1
HWD

Urokinase
Staining in all tubular
epithelial cells, proximal
smooth muscle in
arteries, occasional
plasma cell

Male #2

Good staining in all
tubular epithelium, slight
staining in glomeruli,
sectional staining in
transitional epithelium

Male #3

Good staining in tubular
epithelial cells, cortical
and medullary. Positive
staining along transitional
epithelium. Some
staining in glomeruli.

Male #4

Positive staining on
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Urokinase Receptor
Staining in proximal and
medullary tubules along
basement membrane,
along basilar edge of
tubular epithelial cells,
macrophages
Granular staining along
the basement membrane,
increased in medullary
tubules. Intense in LOH
and some collecting
ducts. Staining
throughout transitional
epithelium on surface
and in cytoplasm
Slight staining on surface
of transitional epithelium.
Light, granular staining
along the basement
membrane of all tubules.
Small amt staining on
apical membrane of the
ureter. Glomeruli
negative
Surface staining on

tubular epithelial cells.
Diffuse pale staining of
the glomeruli. Faint
staining on the surface of
the transitional epithelium

Male #5

Diffuse cytoplasmic
staining in the tubular
cells. Glomeruli negative.
Positive staining in
plasma cells

Male #6

Diffuse staining in the
tubules. Medullary ray
tubules staining more
intently than proximal
convoluted tubules.
Transitional epithelium
staining in sections along
the surface.
Intense staining in the
medullary and cortical
tubules. More intense in
medullary. Good
variability in staining of
the transitional
epithelium. Slight staining
in glomeruli

Male #7

Female #1

Female #2
Female #3

transitional epithelial
membrane. Granular
staining along the
basement membrane of
the medullary tubules
and proximal tubules.
Some staining n apical
membrane of the
proximal tubules
Faint staining along
basement membranes in
the tubules, some on
apical membrane as well.
Faint cytoplasmic
staining in proximal
tubules
Granular basement
membrane staining in
proximal and medullary
tubules.

Very slight staining of
basement membranes of
cortical tubules. Nice
staining in medullary
tubules. Negative
glomeruli. Staining of
transitional epithelium on
surface and within
cytoplasm of cells
Good staining of all
Faint granular staining
tubular epithelial cells. A
along basement
few medullary ray tubules membrane. Most
staining brighter than
prominent in medullar
proximal tubules.
tubules and loops of
Transitional epithelium
henle and collecting
staining in alternating
ducts. Transitional
regions.
epithelium showed
staining along the
surface.
Transitional staining
inconsistently. Maybe
positive in recesses of
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Very faint granular
staining along tubular
basement membrane.

Female #4

pelvis and negative in the
crest. Diffuse proximal
and medullary epithelium.
Faint glomerular staining.
Diffuse interstitial staining
in medulla
Good staining in tubular
epithelial cells. Collecting
ducts staining better than
loop of henle. Glomeruli
negative.

Membrane associated
surface staining on
transitional epithelium

Granular staining along
the basement membrane
of tubular cells.

Key:
Males 1,2,3,4 and 5 – intact males
Males 6 and 7 – castrated males
Females – intact females
Table 5 Immunohistochemistry Results for uPA and uPAR in Ureter Sections
Sample
Urokinase
Urokinase Receptor
Male #1
Uniform positive staining Small amount of granular
of transitional epithelial
staining on the surface of
cells on the surface and
the transitional cells and
in the cytoplasm to the
in the cytoplasm of the
basal cell layers.
cells within the luminal
Inflammatory cells
region. Inflammatory cells
stained positive
stained positive
Male #2
Male #3
Uniform positive staining Mucosa not present on
of transitional epithelial
sample
cells on the surface and
in the cytoplasm to the
basal cell layers.
Inflammatory cells
stained positive
Male #4
Uniform positive staining Nice grainy staining all
of transitional epithelial
along the surface of the
cells on the surface and
transitional epithelium
in the cytoplasm to the
and into the cytoplasm of
basal cell layers.
the first 2 cell layers
Male #5
Uniform positive staining Very slight granular
of transitional epithelial
staining of the cytoplasm
cells on the surface and
of the superficial cell
in the cytoplasm to the
layer in the transitional
basal cell layers.
epithelium. Resident
Inflammatory cells
inflammatory cells
stained positive
stained positive.
Male #6
Uniform positive staining Small amount of granular
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of transitional epithelial
cells on the surface and
in the cytoplasm to the
basal cell layers.
Male #7

Female #1
Female #2
Female #3
Female #4

Uniform positive staining
of transitional epithelial
cells on the surface and
in the cytoplasm to the
basal cell layers.

Uniform positive staining
of transitional epithelial
cells on the surface and
in the cytoplasm to the
basal cell layers.

staining on the surface of
the transitional cells and
in the cytoplasm of the
cells within the luminal
region. Inflammatory cells
stained positive
Very slight granular
staining of the cytoplasm
of the superficial cell
layer in the transitional
epithelium. Resident
inflammatory cells
stained positive.

Very slight granular
staining of the cytoplasm
of the superficial cell
layer in the transitional
epithelium.

Key:
Males 1,2,3,4 and 5 – intact males
Males 6 and 7 – castrated males
Females – intact females
Table 6 Immunohistochemistry Results for uPA and uPAR in Urinary Bladder
Sample
Urokinase
Urokinase Receptor
Male #1
Weak staining on the
Very weak cytoplasmic
surface of transitional
staining in invaginations
epithelium. Resident
of transitional epithelium.
inflammatory cells and
Granular staining on
muscle stained positive.
surface of transitional
Vascular endothelium
epithelium. Inflammatory
stained weakly positive
cells stained positive
Male #2
Transitional epithelium
No mucosa on sample
stained intensely along
Cystitis
the superficial surface
with cytoplasm staining of
deeper cells.
Inflammatory cells
stained positive.
Male #3
Good staining along
Some staining on the
sections of the
apical surface of
transitional epithelium.
transitional epithelium.
Staining is throughout all Some staining in
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Male #4

Male #5

Male #6

Male #7
Female #1

Female #2
Female #3

Female #4
Mild inflammation

cells of the epithelium.
Staining is variable in
sections
Good staining along
sections of the
transitional epithelium.
Vacuolated cytoplasm in
invaginated regions
tended to stain
throughout the cell
layers. Surface staining
was positive on
remaining transitional
epithelium.
Basal layer of transitional
epithelium stained
positive. The overlying
mucosa is missing from
the sample. Smooth
muscle is staining well
No mucosa to evaluate

No mucosa to evaluate
Good staining along
bladder mucosa again in
variable sections.
Staining is apical and
cytoplasm stains better in
invaginations where cell
cytoplasm is vacuolated.
No mucosa to evaluate
Good staining along
bladder mucosa in
variable sections.
Staining is apical and
cytoplasm stains better in
invaginations where cell
cytoplasm is vacuolated.
Occasional inflammatory
cell staining positive
Transitional epithelium
consistently stained well
on the surface and within
the cytoplasm.
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cytoplasm through outer
layer of transitional
epithelium
Granular staining on the
surface and cytoplasmic
staining for 1 to 2 cell
layers within the
transitional epithelium.

No mucosa to evaluate

Granular staining on the
surface and cytoplasmic
staining for 1 to 2 cell
layers within the
transitional epithelium.
No mucosa to evaluate
Granular staining on the
surface of the transitional
epithelium.

No mucosa to evaluate
Granular staining on the
surface of the transitional
epithelium. Granularity
noted around vacuole or
cell membranes at the
surface of the transitional
epithelium
No mucosa to evaluate

Occasional regions
without staining. Positive
staining in inflammatory
cells, smooth muscle and
vascular endothelium.
Key:
Males 1,2,3,4 and 5 – intact males
Males 6 and 7 – castrated males
Females – intact females
Table 7 Immunohistochemistry Results for uPA and uPAR in Urethra
Sample
Urokinase
Urokinase Receptor
Male #1
Positive staining on the
Concentration of granular
surface of the transitional staining in the superficial
Prostatic urethra
epithelium, better in
surface and cytoplasm of
crypts and invaginations. cells of the transitional
Prostatic epithelial cells
epithelium.
near the ureter stain well.
Male #2
Poor sample, mucosa
Poor sample, mucosa
sloughed
sloughed
Male #3
Very intense cytoplasmic
staining along sections of
the transitional epithelium
to sections with no
staining except for along
the luminal surface of the
cells.
Male #4
Very intense cytoplasmic Concentration of granular
staining along sections of staining in the superficial
the transitional epithelium cells of the transitional
to sections with no
epithelium.
staining except for along
the luminal surface of the
cells. Positive staining of
inflammatory cells,
vascular endothelial cells
and some fibroblasts
Male #5
Diffuse staining of the
Intense granular staining
transitional epithelium
in the superficial cells of
from the surface
the transitional
throughout the cytoplasm epithelium, extending into
of the entire layer.
the cytoplasm of the
luminal cell layers.
Male #6
Diffuse light staining of
Slight granular staining in
the transitional epithelium the superficial cells of the
from the surface
transitional epithelium,
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throughout the cytoplasm
of the entire layer.

Male #7

Female #1

Female #2

Female #3
Female #4

extending into the
cytoplasm of the luminal
cell layers. Some
inflammatory cells
staining positive
Very intense cytoplasmic Moderate granular
staining along sections of staining in the superficial
the transitional epithelium cells of the prostatic
to one section with no
urethral transitional
staining except for along epithelium, extending into
the luminal surface of the the cytoplasm of the
cells.
luminal cell layers.
Inflammatory cells
staining intensely
positive. Penile urethra
showed granular staining
along the surface of the
transitional epithelium but
not within the cytoplasm
Muscle and endothelial
cells stained well, no
lumen in the tissue
sample
Good staining of the
Concentration of granular
transitional epithelium on staining in the superficial
surface and within the
surface and cytoplasm of
cytoplasm. Most regions
cells of the transitional
are stained with
epithelium.
occasional areas
unstained through the
cytoplasm. Smoot
muscle, skeletal muscle,
fibroblasts and vascular
endothelial cells are
staining.
No lumen in section
No lumen in section
Surface and cytoplasmic
staining along sections of
the transitional epithelium
to one section with no
staining except for along
the luminal surface of the
cells

Key:
Males 1,2,3,4 and 5 – intact males
Males 6 and 7 – castrated males
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Females – intact females
Table 8 Immunohistochemistry Results for uPA and uPAR in Prostate
Sample
Urokinase
Urokinase Receptor
Male #1
Variable and light
No staining in the
staining of the glandular
glandular epithelium.
Normal, mature
epithelium, most of the
Slight staining in the
glandular tissue is not
ductular epithelium which
staining. Light to
may be transitional
intermediate staining of
epithelium of the prostatic
the muscle. Ducts are not urethra.
staining
Male #2
Glandular cells are
Glandular cells are
negative.
negative. Positive
Mature, hyperplastic
staining of inflammatory
cells.
Male #3
Inflammatory cells
staining well.
Mature, hyperplastic,
poor tissue fixation
Male #4
Not much acinar
Not much acinar
development. Very
development. Granular
Juvenile
positive staining in
staining of the epithelial
developing ducts.
cells of the developing
Staining still present but
ducts and more
slightly less intense in
differentiated ducts,
more differentiated ducts. apical and cytoplasmic.
Positive staining of
Intensity of the staining
inflammatory cells,
appeared equal. Prostatic
smooth muscle cells and urothelium showed
vascular endothelium.
granular staining along
Prostatic urothelium
the surface with some
stained in sections, more cytoplasmic staining in
prominent in the folds.
the superficial cells.
Inflammatory cells
stained brightly
Male #5
Prostatic ducts are
staining well. Very weak
Mature, cystic
to no staining of the
hyperplasia and atrophy
glandular epithelium.
Increased staining of the
cystic glandular
epithelium. Positive
staining of skeletal
muscle.
Male #6
No staining of glands or
No staining on glands or
ducts.
ducts. Inflammatory cells
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Mature
Male #7
Hypoplastic or atrophied

Positive staining of
prostatic epithelial tissue
and ducts, concentrated
in the apical cytoplasm.
Positive staining of
inflammatory cells,
vascular endothelial cells
and transitional
epithelium (in varied
sections)

are staining positive
Small amount of positive
staining around primitive
or poorly developed
ducts. Small amount of
staining on prostatic
urothelium. Inflammatory
cells stained positive.

Key:
Males 1,2,3,4 and 5 – intact males
Males 6 and 7 – castrated males
Table 9 Immunohistochemistry Results for uPA and uPAR in Testicle
Sample
Urokinase
Urokinase Receptor
Male #1
Good staining in
Small amount of granular
seminiferous tubules and cytoplasmic staining in
interstitial cells
some interstitial cells and
faint staining in
contractile myoid cells.
Seminiferous tubules
negative
Male #2
Good staining in
Small amount of granular
seminiferous tubules and cytoplasmic staining in
interstitial cells. Faint
some interstitial cells and
staining in vessel walls.
faint staining in
contractile myoid cells.
Seminiferous tubules
negative
Male #3
Good staining in
Small amount of granular
seminiferous tubules and cytoplasmic staining in
interstitial cells. Staining
some interstitial cells and
not as intense
faint staining in
contractile myoid cells.
Seminiferous tubules
negative
Male #4
Good staining in
Questionable staining in
seminiferous tubules and interstitial cells.
interstitial cells. Faint
staining in vessel walls.
Tunic present and not
staining
Male #5
Intense staining in
Very mild staining in
interstitial cells (leydig
interstitial cells.
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cells). Staining in
seminiferous tubules,
maybe Sertoli cells.
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Seminiferous tubules
negative.
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